[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2011
1. Boldyrev AA, Johnson P: Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis; 2007 May;11(2):219-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease.
  • Homocysteine (HC) and its derivatives may be involved in the etiology of Alzheimer's Disease (AD), although the precise mechanisms by which these compounds could cause cellular pathology are still unclear.
  • Because interactions of HC with glutamate receptors have been implicated in AD, receptor-mediated effects of HC and homocysteic acid (HCA) on neurons and lymphocytes have been analyzed.
  • Activation of glutamate receptors by these compounds has been shown to increase intracellular calcium and free radical levels in both types of cells, which may serve as a signal for development of apoptosis.
  • Activation of group III metabotropic glutamate receptors stimulates, whereas activation of group I and group II metabotropic glutamate receptors prevent, the excitotoxic action of HC and HCA.
  • These effects may contribute to the neuronal pathology and immunosenescence that occur in AD.
  • It is proposed that selective agonists of metabotropic glutamate receptors that counter the effects of HC and its derivatives may be used for correction of neuronal and immune cell metabolism in vivo under the conditions of hyperhomocysteinemia, which can occur in AD.
  • [MeSH-major] Alzheimer Disease / physiopathology. Homocysteine / analogs & derivatives. Homocysteine / pharmacology. Receptors, Glutamate / drug effects
  • [MeSH-minor] Brain / physiopathology. Calcium / metabolism. Cell Death / physiology. Free Radicals / metabolism. Humans. Lymphocytes / drug effects. Neurons / drug effects. Neurons / physiology. Oxidative Stress / physiology. Reactive Oxygen Species / metabolism. Receptors, N-Methyl-D-Aspartate / drug effects

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522446.001).
  • [ISSN] 1387-2877
  • [Journal-full-title] Journal of Alzheimer's disease : JAD
  • [ISO-abbreviation] J. Alzheimers Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Free Radicals; 0 / Reactive Oxygen Species; 0 / Receptors, Glutamate; 0 / Receptors, N-Methyl-D-Aspartate; 0LVT1QZ0BA / Homocysteine; 1001-13-4 / homocysteic acid; SY7Q814VUP / Calcium
  • [Number-of-references] 87
  •  go-up   go-down


2. Moonen H, Engels L, Kleinjans J, Kok Td: The CYP1A2-164A-->C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans. Cancer Lett; 2005 Nov 8;229(1):25-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CYP1A2-164A-->C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans.
  • Colorectal cancer (CRC) is believed to be related to the intake of processed meat and the formed heterocyclic aromatic amines (HCA) herein, which are metabolically activated by the enzymes cytochrome P4501A2 (CYP1A2) and N-acetyltransferase 2 (NAT2).
  • The influence of genotypic and phenotypic variations for CYP1A2 and NAT2 on the risk for colorectal adenomas was investigated in 94 individuals at different risk of developing CRC.
  • Significant associations were found between the CYP1A2-164A-->C polymorphism (CYP1A2*1F) and the risk of colorectal adenomas, suggesting that the studied polymorphism plays an important role in CRC risk in humans.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Cytochrome P-450 CYP1A2 / genetics. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16157215.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


3. Coltro WK, Ferreira MM, Macedo FA, Oliveira CC, Visentainer JV, Souza NE, Matsushita M: Correlation of animal diet and fatty acid content in young goat meat by gas chromatography and chemometrics. Meat Sci; 2005 Oct;71(2):358-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The multivariate methods of hierarchical cluster analysis (HCA) and principal component analysis (PCA) were used to analyze the experimental results.
  • HCA can group samples according to their basic composition, and PCA can explain the relationship among the dietary treatments according to the meat fatty acid composition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22064237.001).
  • [ISSN] 0309-1740
  • [Journal-full-title] Meat science
  • [ISO-abbreviation] Meat Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Hill SE, Bandaria JN, Fox M, Vanderah E, Kohen A, Cheatum CM: Exploring the molecular origins of protein dynamics in the active site of human carbonic anhydrase II. J Phys Chem B; 2009 Aug 20;113(33):11505-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present three-pulse vibrational echo measurements of azide ion bound to the active site Zn of human carbonic anhydrase II (HCA II) and of two separate active-site mutants Thr199 --> Ala (T199A) and Leu198 --> Phe (L198F).
  • Because structural motions of the protein active site influence the frequency of bound ligands, the differences in the time scales of the frequency-frequency correlation functions (FFCFs) obtained from global fits to each set of data allow us to make inferences about the time scales of the active site dynamics of HCA II.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1993 May 10;322(2):186-90 [8482389.001]
  • [Cites] Chemphyschem. 2008 Aug 4;9(11):1536-9 [18613201.001]
  • [Cites] Biochemistry. 1993 Aug 10;32(31):7861-5 [8347590.001]
  • [Cites] Biochemistry. 1995 Mar 28;34(12):3981-9 [7696263.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] Pharmacol Ther. 1997;74(1):1-20 [9336012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15315-20 [9860966.001]
  • [Cites] J Am Chem Soc. 2004 Dec 8;126(48):15702-10 [15571392.001]
  • [Cites] Biochemistry. 2005 Aug 2;44(30):10046-53 [16042381.001]
  • [Cites] J Am Chem Soc. 2005 Sep 21;127(37):12997-3006 [16159295.001]
  • [Cites] J Am Chem Soc. 2005 Oct 19;127(41):14279-89 [16218622.001]
  • [Cites] Acc Chem Res. 2006 Feb;39(2):93-100 [16489728.001]
  • [Cites] J Am Chem Soc. 2006 Mar 29;128(12):3990-7 [16551107.001]
  • [Cites] J Am Chem Soc. 2006 May 10;128(18):6186-93 [16669689.001]
  • [Cites] J Am Chem Soc. 2006 Jun 21;128(24):8015-23 [16771517.001]
  • [Cites] J Phys Chem B. 2005 Sep 8;109(35):16959-66 [16853158.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Aug 29;361(1472):1307-15 [16873118.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Aug 29;361(1472):1323-31 [16873120.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Aug 29;361(1472):1365-73 [16873124.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Aug 29;361(1472):1375-86 [16873125.001]
  • [Cites] Chem Rev. 2006 Aug;106(8):3055-79 [16895318.001]
  • [Cites] Chem Rev. 2006 Aug;106(8):3095-118 [16895320.001]
  • [Cites] Chem Rev. 2006 Aug;106(8):3210-35 [16895325.001]
  • [Cites] J Phys Chem B. 2006 Sep 28;110(38):18933-8 [16986886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2637-42 [17296942.001]
  • [Cites] J Phys Chem B. 2007 Jul 12;111(27):7852-61 [17571875.001]
  • [Cites] J Chem Phys. 2007 Jul 28;127(4):044501 [17672701.001]
  • [Cites] Cell Biochem Biophys. 2007;48(1):32-44 [17703066.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16116-21 [17916624.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):838-44 [18026086.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):913-6 [18026087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19309-14 [18042705.001]
  • [Cites] J Phys Chem B. 2007 Dec 20;111(50):14028-33 [18044873.001]
  • [Cites] J Am Chem Soc. 2008 Jan 9;130(1):22-3 [18067303.001]
  • [Cites] Annu Rev Phys Chem. 2001;52:315-56 [11326068.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2002 May;58(Pt 5):849-52 [11976500.001]
  • [Cites] Eur J Biochem. 2002 Jul;269(13):3103-12 [12084050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6980-5 [12756296.001]
  • [Cites] J Am Chem Soc. 2003 Nov 12;125(45):13804-18 [14599220.001]
  • [Cites] J Chem Phys. 2004 Jul 8;121(2):902-13 [15260622.001]
  • [Cites] J Biol Chem. 1966 Nov 10;241(21):5137-49 [4958988.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1598-603 [1749933.001]
  • [Cites] Eur J Biochem. 1993 Feb 1;211(3):821-7 [8436138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1472-7 [18040050.001]
  • [Cites] J Am Chem Soc. 2008 Jun 11;130(23):7477-88 [18479090.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8619-24 [18562286.001]
  • [Cites] Proteins. 1993 May;16(1):29-42 [8497481.001]
  • (PMID = 19637848.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM065368-06A2; United States / NIGMS NIH HHS / GM / R01 GM065368; United States / NIGMS NIH HHS / GM / R01 GM065368-06A2; United States / NIGMS NIH HHS / GM / R01 GM65368
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; EC 4.2.1.- / Carbonic Anhydrase II
  • [Other-IDs] NLM/ NIHMS135272; NLM/ PMC2736349
  •  go-up   go-down


5. Morsy SM, Badawi AM, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines. J Enzyme Inhib Med Chem; 2009 Apr;24(2):499-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase inhibitors. Biphenylsulfonamides with inhibitory action towards the transmembrane, tumor-associated isozymes IX possess cytotoxic activity against human colon, lung and breast cancer cell lines.
  • The compounds were rather modest inhibitors of isozymes CA I and XII, but were more efficient as inhibitors of the cytosolic CA II and transmembrane, tumor-associated CA IX (inhibition constants in the range of 21-129 nM gainst hCA II, and 23-79 nM against hCA IX, respectively).
  • The new bis-sulfonamides also showed inhibition of growth of several tumor cell lines (ex vivo), with GI(50) values in the range of 0.74-10.0 microg/mL against the human colon cancer cell line HCT116, the human lung cancer cell line H460 and the human breast cancer cell line MCF-7.
  • [MeSH-minor] Breast Neoplasms / enzymology. Breast Neoplasms / metabolism. Colonic Neoplasms / enzymology. Colonic Neoplasms / metabolism. Dose-Response Relationship, Drug. Female. HCT116 Cells. Humans. Isoenzymes / antagonists & inhibitors. Isoenzymes / metabolism. Lung Neoplasms / enzymology. Lung Neoplasms / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608752.001).
  • [ISSN] 1475-6374
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbonic Anhydrase Inhibitors; 0 / Isoenzymes; 0 / Sulfonamides; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


6. Kamiya H, Hagl C, Kropivnitskaya I, Böthig D, Kallenbach K, Khaladj N, Martens A, Haverich A, Karck M: The safety of moderate hypothermic lower body circulatory arrest with selective cerebral perfusion: a propensity score analysis. J Thorac Cardiovasc Surg; 2007 Feb;133(2):501-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The safety of moderate hypothermic lower body circulatory arrest with selective cerebral perfusion: a propensity score analysis.
  • OBJECTIVE: There is no common guideline on what temperature should be achieved at the lower body circulatory arrest followed by the initiation of selective cerebral perfusion.
  • METHODS: Between October 1999 and August 2005, a total of 377 patients underwent repair of the aortic arch with selective cerebral perfusion and hypothermic circulatory arrest at 20 degrees C to 28 degrees C and were divided into two groups:.
  • (1) 125 patients with deep lower body circulatory arrest at 20 degrees C to 24.9 degrees C (deep lower body circulatory arrest group) and (2) 252 patients with moderate lower body circulatory arrest at 25 degrees C to 28 degrees C (moderate lower body circulatory arrest group).
  • To compensate for the differences in patient characteristics, we used a propensity score matching analysis, and comparable patients, 92 patients from each group, were identified for final analysis.
  • RESULTS: There were no significant differences in mortality or morbidity between deep and moderate lower body circulatory arrest, in either the entire study cohort or the propensity-matched cohort.
  • C-reactive protein level 1 day after the operation approached but fell short of significance (108.4 +/- 47.7 mg/L in deep lower body circulatory arrest group and 95.8 +/- 44.2 mg/L in moderate lower body circulatory arrest group, P = .07).
  • The mean temperatures at the initiation of lower body circulatory arrest were 24.1 degrees C +/- 2.2 degrees C in patients who underwent reexploration for bleeding and 24.9 degrees C +/- 1.8 degrees C in patients who did not (P = .025); the difference also reached statistical significance in multivariate analysis (P = .046, odds ratio 0.796).
  • CONCLUSIONS: Our results suggest that moderate lower body circulatory arrest can be safely performed for aortic arch repair.
  • In fact, postoperative inflammatory response tended to be lower in patients with moderate lower body circulatory arrest than those with deep lower body circulatory arrest, and deep lower body circulatory arrest was a strong risk factor for reexploration for bleeding.
  • [MeSH-major] Aorta, Thoracic / surgery. Aortic Aneurysm, Thoracic / mortality. Aortic Aneurysm, Thoracic / surgery. Circulatory Arrest, Deep Hypothermia Induced / methods. Cold Temperature
  • [MeSH-minor] Aged. Analysis of Variance. Case-Control Studies. Cerebrovascular Circulation / physiology. Confidence Intervals. Female. Follow-Up Studies. Hospital Mortality. Humans. Lower Extremity. Male. Middle Aged. Multivariate Analysis. Perfusion / methods. Probability. Retrospective Studies. Risk Assessment. Survival Analysis. Vascular Surgical Procedures / adverse effects. Vascular Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Cardiovasc Surg. 2008 Mar;135(3):715; author reply 715-6 [18329512.001]
  • [CommentIn] J Thorac Cardiovasc Surg. 2008 Mar;135(3):713-4; author reply 714 [18329509.001]
  • (PMID = 17258589.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Fan GJ, Jin XL, Qian YP, Wang Q, Yang RT, Dai F, Tang JJ, Shang YJ, Cheng LX, Yang J, Zhou B: Hydroxycinnamic acids as DNA-cleaving agents in the presence of Cu(II) ions: mechanism, structure-activity relationship, and biological implications. Chemistry; 2009 Nov 23;15(46):12889-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effectiveness of hydroxycinnamic acids (HCAs), that is, caffeic acid (CaA), chlorogenic acid (ChA), sinapic acid (SA), ferulic acid (FA), 3-hydroxycinnamic acid (3-HCA), and 4-hydroxycinnamic acid (4-HCA), as pBR322 plasmid DNA-cleaving agents in the presence of Cu(II) ions was investigated.
  • Compounds bearing o-hydroxy or 3,5-dimethoxy groups on phenolic rings (CaA, SA, and ChA) were remarkably more effective at causing DNA damage than the compounds bearing no such groups; furthermore, CaA was the most active among the HCAs examined.
  • The interaction between CaA and Cu(II) ions and the influence of ethylenediaminetetraacetic acid (EDTA), the solvent, and pH value on the interaction were also studied to help elucidate the detailed prooxidant mechanism by using UV/Vis spectroscopic analysis.
  • Intriguingly, CaA was also the most cytotoxic compound among the HCAs toward human promyelocytic leukemia (HL-60) cell proliferation.
  • Addition of exogenous Cu(II) ions resulted in an effect dichotomy on cell viability depending on the concentration of CaA; that is, low concentrations of CaA enhanced the cell viability and, conversely, high concentrations of CaA almost completely inhibited the cell proliferation.
  • On the other hand, when superoxide dismutase was added before, the two stimulation effects of exogenous Cu(II) ions were significantly ameliorated, thus clearly indicating that the oxidative-stress level regulates cell proliferation and death.
  • [MeSH-minor] Cell Proliferation / drug effects. DNA Breaks / drug effects. Edetic Acid / chemistry. HL-60 Cells. Humans. Hydrogen-Ion Concentration. Oxidation-Reduction. Plasmids / chemistry. Plasmids / metabolism. Reactive Oxygen Species / metabolism. Solvents / chemistry. Spectrophotometry, Ultraviolet. Structure-Activity Relationship

  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847825.001).
  • [ISSN] 1521-3765
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coumaric Acids; 0 / Reactive Oxygen Species; 0 / Solvents; 789U1901C5 / Copper; 9007-49-2 / DNA; 9G34HU7RV0 / Edetic Acid
  •  go-up   go-down


8. Augoustides JG, Andritsos M: Innovations in aortic disease: the ascending aorta and aortic arch. J Cardiothorac Vasc Anesth; 2010 Feb;24(1):198-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Innovations in aortic disease: the ascending aorta and aortic arch.
  • Because preoperative ischemia predicts mortality in type-A dissection, it is logical to classify this disease by ischemic presentation.
  • Aortic arch repairs shorter than 45 minutes in duration are safely performed under deep hypothermic circulatory arrest with/without perfusion adjuncts.
  • Arch repair with ACP and moderate HCA is safe and effective and represents a research opportunity for pharmacologic ischemic preconditioning.

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20006934.001).
  • [ISSN] 1532-8422
  • [Journal-full-title] Journal of cardiothoracic and vascular anesthesia
  • [ISO-abbreviation] J. Cardiothorac. Vasc. Anesth.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 95
  •  go-up   go-down


9. Hoban V: HCAs in nursing: what role should they play? Nurs Times; 2008 May 20-26;104(20):18-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCAs in nursing: what role should they play?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546986.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Urbanski PP, Lenos A, Zacher M, Diegeler A: Unilateral cerebral perfusion: right versus left. Eur J Cardiothorac Surg; 2010 Jun;37(6):1332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Arch repair was performed under mild hypothermic circulatory arrest with a rectal temperature of 30.1 + or - 1.8 degrees C and 31.6 + or - 1.6 degrees C in the left- and right-sided cerebral perfusion, respectively.
  • The duration of circulatory arrest with unilateral cerebral perfusion was identical for both groups (17.2 + or - 2 min).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur J Cardiothorac Surg. 2010 Jun;37(6):1336-7 [20233661.001]
  • [CommentIn] Eur J Cardiothorac Surg. 2012 Jun;41(6):1406; author reply 1406-7 [22228847.001]
  • (PMID = 20444617.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Meyer L, Bednarz J, Müller-Goymann CC, Reichl S: [Esterase activity of human organotypic cornea construct (HCC) as in vitro model for permeation studies]. Ophthalmologe; 2005 Oct;102(10):971-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The esterase activity of three corneal human cell lines (epithelial, stromal, endothelial cells) as well as of excised porcine cornea, human donor cornea and human cornea construct (HCC) was investigated and compared.
  • Esterase activity was determined using p-nitrophenyl acetate and hydrocortisone acetate (HCA) as esterase substrates.
  • Hydrocortisone acetate permeation across porcine cornea, human donor cornea and HCC was studied in vitro using Franz-diffusion cells.
  • Corneal epithelial cells showed the highest esterase activity and only small differences to keratocytes and endothelial cells were detectable.
  • The permeation barrier properties of the different corneal tissues were very similar in the case of HCA permeation whereas HCA metabolism rates were in the ranking order of porcine cornea > HCC > human donor cornea.
  • [MeSH-minor] Aged. Animals. Biological Availability. Cells, Cultured. Corneal Stroma / drug effects. Corneal Stroma / enzymology. Corneal Stroma / metabolism. Endothelium, Corneal / cytology. Endothelium, Corneal / drug effects. Endothelium, Corneal / metabolism. Epithelium, Corneal / cytology. Epithelium, Corneal / drug effects. Epithelium, Corneal / enzymology. Epithelium, Corneal / metabolism. Humans. Hydrocortisone / analogs & derivatives. Hydrocortisone / metabolism. Microscopy, Phase-Contrast. Middle Aged. Organ Culture Techniques. Permeability. Prodrugs / pharmacokinetics. Swine. Time Factors. Tissue Donors

  • Genetic Alliance. consumer health - Hepatocellular carcinoma, adult.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2942-8 [11687540.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Oct;35(9):515-26 [10548433.001]
  • [Cites] Br J Ophthalmol. 2004 Apr;88(4):560-5 [15031177.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2169-72 [10591651.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Apr;78(2):130-6 [10794243.001]
  • [Cites] Eur J Pharm Sci. 2003 Sep;20(1):99-106 [13678798.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2316-24 [7685009.001]
  • [Cites] Am J Ophthalmol. 1978 Mar;85(3):383-6 [655217.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 May;40(6):1091-101 [10235542.001]
  • [Cites] Ophthalmic Res. 2001 Jan-Feb;33(1):1-6 [11114598.001]
  • [Cites] J Ocul Pharmacol Ther. 2002 Oct;18(5):455-68 [12419096.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Mar;36(3):614-21 [7534282.001]
  • [Cites] Ophthalmic Res. 1993;25(1):46-51 [8446367.001]
  • [Cites] Curr Eye Res. 1998 Feb;17(2):125-31 [9523089.001]
  • [Cites] Ophthalmologe. 2001 Sep;98(9):853-8 [11594225.001]
  • [Cites] J Pharm Sci. 1999 Feb;88(2):180-4 [9950635.001]
  • [Cites] J Ocul Pharmacol. 1985 Fall;1(3):309-26 [3916851.001]
  • [Cites] Pharm Res. 2002 Aug;19(8):1194-202 [12240946.001]
  • [Cites] J Pharm Sci. 2001 Oct;90(10):1505-15 [11745709.001]
  • [Cites] J Ocul Pharmacol Ther. 2001 Apr;17 (2):159-72 [11324983.001]
  • [Cites] J Pharm Sci. 1983 Mar;72(3):239-44 [6842375.001]
  • [Cites] Pharm Res. 2000 Jun;17(6):670-6 [10955839.001]
  • [Cites] Eur J Pharm Biopharm. 2005 Jul;60(2):305-8 [15939241.001]
  • [Cites] Biopharm Drug Dispos. 1982 Oct-Dec;3(4):291-300 [7159685.001]
  • [Cites] Eur J Pharm Biopharm. 2001 Mar;51(2):119-25 [11226818.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1994 Mar;232(3):182-91 [8188069.001]
  • [Cites] J Ocul Pharmacol Ther. 2002 Dec;18(6):535-48 [12537680.001]
  • [Cites] Ophthalmologe. 2003 Sep;100(9):696-701 [14504893.001]
  • (PMID = 15785910.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ophthalmic Solutions; 0 / Prodrugs; 3X7931PO74 / hydrocortisone acetate; EC 3.1.- / Esterases; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


12. Salmona J, Dussert S, Descroix F, de Kochko A, Bertrand B, Joët T: Deciphering transcriptional networks that govern Coffea arabica seed development using combined cDNA array and real-time RT-PCR approaches. Plant Mol Biol; 2008 Jan;66(1-2):105-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deciphering transcriptional networks that govern Coffea arabica seed development using combined cDNA array and real-time RT-PCR approaches.
  • The aim of the present study was to decipher the transcriptional networks that govern the development of the C. arabica seed, a model for non-orthodox albuminous seeds of tropical origin.
  • For this purpose, we developed a transcriptomic approach combining two techniques: targeted cDNA arrays, containing 266 selected candidate gene sequences, and real-time RT-PCR on a large subset of 111 genes.
  • The combination of the two techniques allowed us to limit detection of false positives and to reveal the advantages of using large real-time RT-PCR screening.
  • Multivariate analysis was conducted on both datasets and results were broadly convergent.
  • First, principle component analysis (PCA) revealed a dramatic re-programming of the transcriptional machinery between early cell division and elongation, storage and maturation phases.
  • Second, hierarchical clustering analysis (HCA) led to the identification of 11 distinct patterns of gene expression during seed development as well as to the detection of genes expressed at specific developmental stages that can be used as functional markers of phenological changes.
  • [MeSH-minor] Base Sequence. DNA, Complementary. Genes, Plant. Multigene Family. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2004 Jan 16;303(5656):363-6 [14726589.001]
  • [Cites] Theor Appl Genet. 2005 Oct;111(6):1032-41 [16133319.001]
  • [Cites] Plant Physiol. 2005 Jan;137(1):354-68 [15618428.001]
  • [Cites] Plant Physiol. 2000 Dec;124(4):1570-81 [11115875.001]
  • [Cites] J Plant Physiol. 2006 May;163(7):691-708 [16442665.001]
  • [Cites] Plant J. 1997 Mar;11(3):539-48 [9107040.001]
  • [Cites] Plant Physiol Biochem. 2005 Oct-Nov;43(10-11):909-20 [16310367.001]
  • [Cites] Nat Biotechnol. 2006 Sep;24(9):1115-22 [16964225.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Neurosci Lett. 2003 Mar 13;339(1):62-6 [12618301.001]
  • [Cites] Theor Appl Genet. 2003 Aug;107(4):751-6 [12861362.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Nat Rev Genet. 2001 Jun;2(6):418-27 [11389458.001]
  • [Cites] Mol Genet Genomics. 2006 Nov;276(5):436-49 [16924545.001]
  • [Cites] BMC Bioinformatics. 2006 Apr 07;7:194 [16600052.001]
  • [Cites] Phytochemistry. 2000 Oct;55(4):285-96 [11117875.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14363-6 [11882647.001]
  • [Cites] Planta. 1972 Dec;108(4):339-50 [24473913.001]
  • [Cites] Plant Physiol. 2004 Nov;136(3):3427-34 [15542496.001]
  • [Cites] Theor Appl Genet. 2005 Dec;112(1):114-30 [16273343.001]
  • [Cites] Trends Plant Sci. 2001 Sep;6(9):431-8 [11544133.001]
  • [Cites] Plant J. 2004 Feb;37(4):539-53 [14756762.001]
  • [Cites] FEBS Lett. 2003 Jul 17;547(1-3):56-60 [12860386.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Ann Bot. 2006 May;97(5):755-65 [16504969.001]
  • [Cites] Plant Mol Biol. 2007 May;64(1-2):145-59 [17333503.001]
  • [Cites] Plant Physiol. 2003 Jun;132(2):681-97 [12805597.001]
  • [Cites] Trends Genet. 2006 Feb;22(2):101-9 [16380191.001]
  • [Cites] J Exp Bot. 2006;57(12):3243-58 [16926239.001]
  • [Cites] Plant Physiol. 2003 May;132(1):372-80 [12746542.001]
  • [Cites] BMC Genomics. 2005 Apr 27;6:59 [15854232.001]
  • [Cites] Plant Cell. 2002 Jun;14(6):1191-206 [12084821.001]
  • [Cites] Plant Cell. 2005 Apr;17(4):1061-72 [15749756.001]
  • [Cites] Plant Biotechnol J. 2003 Jan;1(1):59-70 [17147681.001]
  • [Cites] Mol Genet Genomics. 2007 Jun;277(6):701-12 [17318584.001]
  • [Cites] Mol Gen Genet. 1998 Jul;259(1):88-96 [9738884.001]
  • [Cites] Nature. 2000 Dec 14;408(6814):796-815 [11130711.001]
  • [Cites] Planta. 2003 Jun;217(2):316-26 [12783340.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8213-8 [11108716.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5676-84 [14500831.001]
  • [Cites] Plant J. 2004 Apr;38(2):366-79 [15078338.001]
  • [Cites] Funct Integr Genomics. 2002 May;2(1-2):13-27 [12021847.001]
  • [Cites] Nucleic Acids Res. 2002 May 15;30(10):e48 [12000853.001]
  • (PMID = 18026845.001).
  • [ISSN] 0167-4412
  • [Journal-full-title] Plant molecular biology
  • [ISO-abbreviation] Plant Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Complementary
  •  go-up   go-down


13. Fraser CD 3rd, Arnaoutakis GJ, George TJ, Owens JB, Conte JV, Shah AS: Acute cholecystitis preceding mycotic aortic pseudoaneurysm in a heart transplant recipient. J Card Surg; 2010 Nov;25(6):749-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute cholecystitis preceding mycotic aortic pseudoaneurysm in a heart transplant recipient.
  • Mycotic pseudoaneurysm is a rare complication after orthotopic heart transplantation (OHT).
  • The region of involved aorta was effectively repaired using a patch of bovine pericardium and a brief period of hypothermic circulatory arrest.
  • [MeSH-major] Aneurysm, False / surgery. Aneurysm, Infected / surgery. Aortic Rupture / surgery. Candidiasis / surgery. Cholecystitis, Acute / complications. Heart Transplantation. Postoperative Complications


14. Temperini C, Innocenti A, Scozzafava A, Supuran CT: Carbonic anhydrase activators: kinetic and X-ray crystallographic study for the interaction of D- and L-tryptophan with the mammalian isoforms I-XIV. Bioorg Med Chem; 2008 Sep 15;16(18):8373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The high resolution X-ray crystal structure of the hCA II-D-Trp adduct revealed the activator to bind in a totally unprecedented way to the enzyme active site as compared to histamine, L-/D-Phe, L-/D-His or L-adrenaline.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774300.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Activators; 0 / Protein Isoforms; 47E5O17Y3R / Phenylalanine; 820484N8I3 / Histamine; 8DUH1N11BX / Tryptophan; EC 4.2.1.1 / Carbonic Anhydrases; YKH834O4BH / Epinephrine
  •  go-up   go-down


15. Wang GS, Cui WW, Wu BY, Wang MW: [Gene expression profile of human normal gastrointestinal tract tissues: bioinformatic study]. Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2008 Aug;24(3):334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Online software including Ingenuity and KEGG were applied for physiological function analyses.
  • Unsupervised two-way hierarchical clustering method was used to analyze the expression profile of stomach-specific genes in gastric cancer gene expression datasets.
  • RESULTS: The analyses identified 196 stomach-specific genes, 203 ileum-specific genes and 224 colon-specific genes, respectively.
  • Hierarchical clustering analysis revealed that the stomach-specific genes were up-regulated in normal stomach tissues but down-regulated in stomach cancer tissues.
  • At the meantime, clustering could also distinguish the moderate and severe differentiated stomach cancer.
  • [MeSH-minor] Cluster Analysis. Colon / metabolism. Computational Biology. Databases, Genetic. Gene Expression Profiling. Humans. Ileum / metabolism. Stomach / metabolism. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141596.001).
  • [ISSN] 1000-6834
  • [Journal-full-title] Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
  • [ISO-abbreviation] Zhongguo Ying Yong Sheng Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Mitić MN, Obradović MV, Grahovac ZB, Pavlović AN: Antioxidant capacities and phenolic levels of different varieties of Serbian white wines. Molecules; 2010 Mar;15(3):2016-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biologically active compounds in wine, especially phenolics, are responsible for reduced risk of developing chronic diseases (cardiovascular disease, cancer, diabetes, etc.
  • Total antioxidant activity (TAA) of the white wines was analyzed using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging capacity assay.
  • The majority of white wine polyphenols was represent by four hydroxycinnamic acids (HCAs).
  • [MeSH-major] Antioxidants / chemistry. Phenols / analysis. Wine / analysis
  • [MeSH-minor] Chromatography, High Pressure Liquid. Principal Component Analysis

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20336029.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Phenols
  •  go-up   go-down


17. Al-Buheissi SZ, Cole KJ, Hewer A, Kumar V, Bryan RL, Hudson DL, Patel HR, Nathan S, Miller RA, Phillips DH: The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures. Prostate; 2006 Jun 1;66(8):876-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of xenobiotic-metabolizing enzymes in human prostate and in prostate epithelial cells (PECs) derived from primary cultures.
  • BACKGROUND: Dietary heterocyclic amines (HCAs) are carcinogenic in rodent prostate requiring activation by enzymes such as cytochrome P450 (CYP) and N-acetyltransferase (NAT).
  • METHODS: We investigated by Western blotting and immunohistochemistry the expression of CYP1A1, CYP1A2, and NAT1 in human prostate and in prostate epithelial cells (PECs) derived from primary cultures and tested their ability to activate the dietary carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and its N-hydroxy metabolite (N-OH-IQ) to DNA-damaging moieties.
  • CONCLUSIONS: Prostate cells possess the capacity to activate dietary carcinogens.
  • [MeSH-major] Arylamine N-Acetyltransferase / analysis. Cytochrome P-450 CYP1A1 / analysis. Cytochrome P-450 CYP1A2 / analysis. Epithelial Cells / enzymology. Imidazoles / metabolism. Isoenzymes / analysis. Prostate / enzymology. Quinolines / metabolism. Xenobiotics / metabolism
  • [MeSH-minor] Biotransformation. Blotting, Western. Carcinogens / metabolism. Cells, Cultured. DNA Adducts. DNA, Neoplasm / analysis. Gene Expression Regulation, Enzymologic. Humans. Immunohistochemistry. Male

  • Hazardous Substances Data Bank. 2-AMINO-3-METHYLIMIDAZO(4,5-f)QUINOLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496416.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA Adducts; 0 / DNA, Neoplasm; 0 / Imidazoles; 0 / Isoenzymes; 0 / Quinolines; 0 / Xenobiotics; 76180-96-6 / 2-amino-3-methylimidazo(4,5-f)quinoline; 77314-23-9 / 2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1A2; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1
  •  go-up   go-down


18. Arbona V, Iglesias DJ, Talón M, Gómez-Cadenas A: Plant phenotype demarcation using nontargeted LC-MS and GC-MS metabolite profiling. J Agric Food Chem; 2009 Aug 26;57(16):7338-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Result validation was achieved with principal component analysis (PCA).
  • The ability of the profiling methodologies to discriminate plant genotypes was assessed after hierarchical clustering analysis (HCA).
  • A better performance of LC-MS profiling over GC-MS was evidenced in terms of phenotype demarcation after PCA and HCA.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639992.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Galloro V: HCA scores on bond market. First-quarter earnings expected to top $600 million. Mod Healthc; 2009 Apr 20;39(16):12-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA scores on bond market. First-quarter earnings expected to top $600 million.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422133.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


20. Wellen JR, Anderson CD, Doyle M, Shenoy S, Nadler M, Turmelle Y, Shepherd R, Chapman WC, Lowell JA: The role of liver transplantation for hepatic adenomatosis in the pediatric population: case report and review of the literature. Pediatr Transplant; 2010 May;14(3):E16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of liver transplantation for hepatic adenomatosis in the pediatric population: case report and review of the literature.
  • Hepatic adenomas are benign lesions often found in young women during childbearing age.
  • These tumors are often solitary but can also be multiple in which case this is referred to as hepatic adenomatosis (HA).
  • HA is defined as having greater than or equal to ten adenomas within an otherwise normal liver.
  • We present a case of a teenager with HA who underwent an orthotopic liver transplant for complications of her HA.
  • To date there are only four reports of teenagers, without an underlying glycogen storage disease, who have undergone a liver transplant for HA.
  • Liver transplantation within the pediatric population is an acceptable treatment for HA that are deemed unresectable.
  • [MeSH-major] Adenoma, Liver Cell / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adolescent. Biopsy. Female. Humans. Liver Function Tests


21. Nakamura N, Kobayashi K, Nakamoto M, Kohno T, Sasaki H, Matsuno Y, Yokota J: Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene; 2006 Jul 13;25(30):4245-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma.
  • To identify tumor markers and differentiation markers for lung adenocarcinoma (AdC), we analysed expression profiles of 14,500 genes against three cases of type II alveolar epithelial cells, bronchiolar epithelial cells, and bronchial epithelial cells, respectively, and 10 cases of AdC cells isolated by laser capture microdissection.
  • Hierarchical clustering analysis indicated that AdC cells and noncancerous lung epithelial cells are significantly different in their expression profiles, and that different sets of differentiation markers are expressed among alveolar, bronchiolar and bronchial epithelial cells.
  • Nine genes were identified as being highly expressed in AdC cells, but not expressed in noncancerous lung epithelial cells.
  • Sixteen genes were identified as differentiation markers for lung epithelial cells.
  • Real-time RT-PCR analysis of 45 lung AdC cases further revealed that expression of four tumor markers in AdC cells was significantly higher than that in noncancerous lung cells and that expression of ten differentiation markers was retained in a considerable fraction of lung AdC cases.
  • Five tumor markers and seven differentiation markers were not expressed in peripheral blood cells.
  • Similarities and differences in expression profiles between normal epithelial cells from different lung respiratory compartments and AdC cells demonstrated in this study will be informative for the molecular diagnosis of lung AdC.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Biomarkers, Tumor. Cell Differentiation. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology
  • [MeSH-minor] Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. Respiratory Mucosa / chemistry. Respiratory Mucosa / cytology. Respiratory Mucosa / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491115.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Gorayski P, Thompson CH, Subhash HS, Thomas AC: Hepatocellular carcinoma associated with recreational anabolic steroid use. Br J Sports Med; 2008 Jan;42(1):74-5; discussion 75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma associated with recreational anabolic steroid use.
  • A 35-year-old male bodybuilder was found to have a hepatocellular carcinoma (HCC) arising in a pre-existing hepatic adenoma following recreational anabolic steroid use.
  • Given the widespread use of recreational anabolic steroids, another potentially life-threatening complication is highlighted in addition to the more commonly recognised hepatic adenoma.
  • Malignant transformation to HCC from a pre-existing hepatic adenoma confirmed by immunohistochemical study has previously not been reported in athletes taking anabolic steroids.
  • [MeSH-major] Anabolic Agents / adverse effects. Carcinoma, Hepatocellular / chemically induced. Liver Neoplasms / chemically induced. Weight Lifting
  • [MeSH-minor] Adenoma / pathology. Adult. Cell Transformation, Neoplastic / drug effects. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Anabolic Steroids.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Sports Med. 2009 Oct 1;43(10):764
  • [ErratumIn] Br J Sports Med. 2010 Oct;44(13):e5
  • (PMID = 18178686.001).
  • [ISSN] 1473-0480
  • [Journal-full-title] British journal of sports medicine
  • [ISO-abbreviation] Br J Sports Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anabolic Agents
  •  go-up   go-down


23. Harvey I, Schulz A, Israel B, Sand S, Myrie D, Lockett M, Weir S, Hill Y: The Healthy Connections project: a community-based participatory research project involving women at risk for diabetes and hypertension. Prog Community Health Partnersh; 2009;3(4):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: This community-based participatory research (CBPR) project involved identifying and training CHWs, known as HC Advocates (HCAs).
  • The HCAs provided screening through House Parties and shared health information and practical support with members of their social networks and broader networks of individuals.
  • METHODS: Data collection methods included project documentation, participant observation, group interviews, closed-ended surveys, and written examinations to ensure HCAs had the required knowledge and skills to perform their roles.
  • Data collection and analysis incorporated both qualitative and quantitative methods, and used a formative approach that integrated results from key aspects of the project into ongoing decision-making and project activities.
  • RESULTS: Eight community residents completed training and the required exams to become HCAs.
  • Together, they conducted 124 House Parties, screened 1,428 individuals for high blood pressure and glucose levels, and shared health information with those individuals as well as 218 additional members of HCAs informal social networks.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20097990.001).
  • [ISSN] 1557-0541
  • [Journal-full-title] Progress in community health partnerships : research, education, and action
  • [ISO-abbreviation] Prog Community Health Partnersh
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Braeuning A, Singh Y, Rignall B, Buchmann A, Hammad S, Othman A, von Recklinghausen I, Godoy P, Hoehme S, Drasdo D, Hengstler JG, Schwarz M: Phenotype and growth behavior of residual β-catenin-positive hepatocytes in livers of β-catenin-deficient mice. Histochem Cell Biol; 2010 Nov;134(5):469-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Signaling through the Wnt/β-catenin pathway is a crucial determinant of hepatic zonal gene expression, liver development, regeneration, and tumorigenesis.
  • The remaining β-catenin-positive hepatocytes showed approximately 25% higher cell volumes compared to the β-catenin-negative cells and exhibited a marker protein expression profile similar to that of normal perivenous hepatocytes or hepatoma cells with mutationally activated β-catenin.
  • Surprisingly, the expression pattern was observed independent of the cell's position within the liver lobule, suggesting a malfunction of physiological periportal repression of perivenously expressed genes in β-catenin-deficient liver.
  • Nonetheless, β-catenin-positive hepatocytes had no striking proliferative advantage, but started to grow out on treatment with phenobarbital, a tumor-promoting agent known to facilitate the formation of mouse liver adenoma with activating mutations of Ctnnb1.
  • [MeSH-minor] Animals. Carcinogens / pharmacology. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Proliferation. Cell Separation. Cell Size. Connexins / deficiency. Cytochrome P-450 CYP2E1 / metabolism. DNA Mutational Analysis. Disease Models, Animal. Female. Gene Expression. Glutamate-Ammonia Ligase / metabolism. Liver / drug effects. Liver / enzymology. Liver / pathology. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Male. Mice. Mice, Inbred C3H. Mice, Knockout. Phenobarbital / pharmacology. Phenotype. RNA, Messenger / metabolism

  • Hazardous Substances Data Bank. Phenobarbital .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Metab Dispos. 2009 May;37(5):1138-45 [19237511.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):763-8 [15338370.001]
  • [Cites] Hepatology. 2007 May;45(5):1298-305 [17464972.001]
  • [Cites] Physiol Rev. 1989 Jul;69(3):708-64 [2664826.001]
  • [Cites] Histochemistry. 1990;94(1):49-54 [1972146.001]
  • [Cites] Hepatology. 2009 Jun;49(6):2031-43 [19274752.001]
  • [Cites] Curr Opin Genet Dev. 1998 Feb;8(1):95-102 [9529612.001]
  • [Cites] Toxicol Sci. 2010 May;115(1):22-33 [20118494.001]
  • [Cites] Biol Chem. 2010 Feb-Mar;391(2-3):139-48 [20030591.001]
  • [Cites] Hepatology. 2006 Mar;43(3):407-14 [16496347.001]
  • [Cites] Histochem Cell Biol. 1995 Feb;103(2):81-91 [7634156.001]
  • [Cites] Biochem J. 1998 Jan 1;329 ( Pt 1):17-35 [9405271.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Sep 30;139(3):1055-61 [3021146.001]
  • [Cites] J Biol Chem. 1999 Jan 22;274(4):2157-65 [9890978.001]
  • [Cites] Gen Pharmacol. 1997 Feb;28(2):191-6 [9013193.001]
  • [Cites] J Membr Biol. 2007 Aug;218(1-3):79-91 [17653785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10371-6 [20484673.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5087-91 [11016633.001]
  • [Cites] Hepatology. 2007 Sep;46(3):861-70 [17668884.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5685-8 [12384525.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):48-54 [14729607.001]
  • [Cites] Mol Cell Biol. 1991 Dec;11(12):6050-8 [1682797.001]
  • [Cites] Hepatology. 2007 Feb;45(2):361-8 [17256747.001]
  • [Cites] Dev Cell. 2006 Jun;10(6):759-70 [16740478.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1971-7 [11929813.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):674-87 [16929323.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] EMBO J. 1983;2(4):567-70 [6138251.001]
  • [Cites] Hepatology. 2006 Apr;43(4):817-25 [16557553.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2304-2315.e1-4 [19272382.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1561-72 [17101329.001]
  • [Cites] Hepatology. 2010 Sep;52(3):954-65 [20583210.001]
  • [Cites] Pharmacol Ther. 1992;53(3):275-354 [1409850.001]
  • [Cites] Histochem Cell Biol. 2007 Aug;128(2):105-14 [17576590.001]
  • [Cites] Oncogene. 2002 Nov 28;21(54):8293-301 [12447692.001]
  • [Cites] Cell. 2001 May 18;105(4):533-45 [11371349.001]
  • [Cites] Drug Metab Dispos. 2007 Apr;35(4):503-7 [17220236.001]
  • [Cites] Future Oncol. 2008 Oct;4(5):647-60 [18922122.001]
  • [Cites] J Hepatol. 2005 Jul;43(1):126-31 [15876469.001]
  • [Cites] Toxicol Sci. 2008 Jun;103(2):260-7 [18308698.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):215-9 [15050913.001]
  • [Cites] Carcinogenesis. 1995 Aug;16(8):1673-81 [7634388.001]
  • [Cites] Annu Rev Nutr. 1996;16:179-203 [8839925.001]
  • [Cites] Oncogene. 2001 Nov 22;20(53):7812-6 [11753661.001]
  • [Cites] Cell Biol Toxicol. 1997 Jul;13(4-5):263-73 [9298247.001]
  • [Cites] Eur J Cell Biol. 1990 Oct;53(1):35-41 [1981746.001]
  • [Cites] Toxicol Sci. 2006 Sep;93(1):34-40 [16782779.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):239-48 [15471898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17216-21 [15563600.001]
  • (PMID = 20886225.001).
  • [ISSN] 1432-119X
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / Carcinogens; 0 / Connexins; 0 / RNA, Messenger; 0 / beta Catenin; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 6.3.1.2 / Glutamate-Ammonia Ligase; YQE403BP4D / Phenobarbital
  •  go-up   go-down


25. Chen HL, D'Mello SR: Induction of neuronal cell death by paraneoplastic Ma1 antigen. J Neurosci Res; 2010 Dec;88(16):3508-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of neuronal cell death by paraneoplastic Ma1 antigen.
  • Paraneoplastic Ma1 (PNMA1) is a member of a family of proteins involved in an autoimmune disorder called paraneoplastic neurological syndrome.
  • PNMA1 expression increases in cerebellar granule neurons (CGNs) induced to die by low potassium (LK) and in cortical neurons following homocysteic acid (HCA) treament.
  • Elevated PNMA1 expression is also observed in the degenerating striatum in two separate mouse models of Huntington's disease, the R6/2 transgenic model and the 3-nitropropionic acid-induced chemical model.
  • Deletion of the N-terminal half of the PNMA1 protein abrogates its apoptotic activity, whereas deletion of the C-terminal half renders the protein more toxic.

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • (PMID = 20936693.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS040408; United States / NINDS NIH HHS / NS / R01 NS047201; United States / NINDS NIH HHS / NS / NS047201; United States / NINDS NIH HHS / NS / NS40408
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Ma1 antigen; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ NIHMS752997; NLM/ PMC4727899
  •  go-up   go-down


26. Mellits KH, Connerton IF, Loughlin MF, Clarke P, Smith J, Dillon E, Connerton PL, Mulholland F, Hawkey CJ: Induction of a chemoattractant transcriptional response by a Campylobacter jejuni boiled cell extract in colonocytes. BMC Microbiol; 2009 Feb 04;9:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of a chemoattractant transcriptional response by a Campylobacter jejuni boiled cell extract in colonocytes.
  • To understand how a previously identified heat stable component contributes to pro-inflammatory responses we used microarray and real-time quantitative PCR to investigate the transcriptional response to a boiled cell extract of Campylobacter jejuni NCTC 11168.
  • RESULTS: RNA was extracted from the human colonocyte line HCA-7 (clone 29) after incubation for 6 hours with Campylobacter jejuni boiled cell extract and was used to probe the Affymetrix Human Genome U133A array.
  • Genes differentially affected by Campylobacter jejuni boiled cell extract were identified using the Significance Score algorithm of the Bioconductor software suite and further analyzed using the Ingenuity Pathway Analysis program.
  • Ingenuity Pathway Analysis also identified the most affected functional gene networks such as cell movement, gene expression and cell death.
  • CONCLUSION: A boiled cell extract of Campylobacter jejuni has components that can directly switch the phenotype of colonic epithelial cells from one of resting metabolism to a pro-inflammatory one, particularly characterized by increased expression of genes for leukocyte chemoattractant molecules.
  • [MeSH-major] Campylobacter jejuni / chemistry. Campylobacter jejuni / immunology. Chemotactic Factors / immunology. Colon / immunology. Epithelial Cells / immunology. Gene Expression Profiling
  • [MeSH-minor] Cell Line. Chemokines / biosynthesis. Down-Regulation. Humans. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / immunology. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Liver Dis. 2008 Nov;40(11):867-73 [18499543.001]
  • [Cites] World J Gastroenterol. 2008 Dec 28;14(48):7345-52 [19109868.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3452-7 [11151876.001]
  • [Cites] Adv Exp Med Biol. 1999;473:215-24 [10659361.001]
  • [Cites] Nature. 2000 Feb 10;403(6770):665-8 [10688204.001]
  • [Cites] Biochem Pharmacol. 2000 Oct 15;60(8):1143-51 [11007952.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2673-81 [11023497.001]
  • [Cites] Infect Immun. 2000 Dec;68(12):6535-41 [11083762.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jan;33(1):19-32 [11167129.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):30216-23 [11390377.001]
  • [Cites] Respir Res. 2000;1(2):87-92 [11667971.001]
  • [Cites] Nature. 2002 Mar 21;416(6878):345-7 [11907583.001]
  • [Cites] Curr Drug Metab. 2002 Apr;3(2):211-23 [12003352.001]
  • [Cites] Int J Food Microbiol. 2002 Jun 5;76(1-2):151-64 [12038572.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86 [12094214.001]
  • [Cites] Microbiology. 2002 Sep;148(Pt 9):2753-63 [12213922.001]
  • [Cites] Cell. 2002 Nov 27;111(5):635-46 [12464176.001]
  • [Cites] Gut. 2003 Jan;52(1):65-70 [12477762.001]
  • [Cites] Bioinformatics. 2003 Jan;19(1):155-6 [12499308.001]
  • [Cites] FEBS Lett. 2003 Feb 11;536(1-3):135-40 [12586352.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):1955-64 [12673201.001]
  • [Cites] Infect Immun. 2003 May;71(5):2626-33 [12704137.001]
  • [Cites] Curr Allergy Asthma Rep. 2004 Jan;4(1):83-9 [14680627.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] Cell. 2004 Apr 16;117(2):211-23 [15084259.001]
  • [Cites] Trends Biochem Sci. 2004 Feb;29(2):72-9 [15102433.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):414-6 [15149588.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):416-8 [15149589.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):661-9 [15224091.001]
  • [Cites] Arch Pathol Lab Med. 1980 Nov;104(11):571-4 [6893534.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3790-5 [4016751.001]
  • [Cites] Clin Sci (Lond). 1992 Mar;82(3):273-5 [1312411.001]
  • [Cites] Nature. 1996 Jan 25;379(6563):349-53 [8552191.001]
  • [Cites] Gut. 1996 Aug;39(2):248-54 [8977339.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Oct 1;286(5437):113-7 [10506557.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):917-21 [15531878.001]
  • [Cites] Crit Rev Immunol. 2005;25(1):31-58 [15833082.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] Lett Appl Microbiol. 2005;41(4):297-302 [16162134.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:35-56 [16212486.001]
  • [Cites] Lancet. 2005 Nov 5;366(9497):1653-66 [16271648.001]
  • [Cites] Cell Mol Immunol. 2006 Feb;3(1):35-40 [16549047.001]
  • [Cites] Bioinformatics. 2006 May 15;22(10):1272-4 [16574698.001]
  • [Cites] Biometals. 2006 Apr;19(2):211-5 [16718606.001]
  • [Cites] APMIS. 2006 Jul-Aug;114(7-8):508-17 [16907856.001]
  • [Cites] FEMS Microbiol Lett. 2006 Sep;262(2):236-43 [16923081.001]
  • [Cites] Inflamm Bowel Dis. 2006 Sep;12(9):837-42 [16954802.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9245-51 [16982769.001]
  • [Cites] Cell Cycle. 2006 Oct;5(20):2332-8 [17102623.001]
  • [Cites] Crit Rev Microbiol. 2006 Oct-Dec;32(4):227-48 [17123907.001]
  • [Cites] Clin Immunol. 2007 Mar;122(3):288-97 [17178254.001]
  • [Cites] Cardiovasc Toxicol. 2006;6(2):111-30 [17303919.001]
  • [Cites] Nature. 2007 Mar 15;446(7133):329-32 [17361185.001]
  • [Cites] Clin Exp Immunol. 2007 Sep;149(3):480-6 [17590175.001]
  • [Cites] Nat Rev Microbiol. 2007 Sep;5(9):665-79 [17703225.001]
  • [Cites] Gut. 2007 Oct;56(10):1333-6 [17872562.001]
  • [Cites] World J Gastroenterol. 2007 Nov 14;13(42):5560-70 [17948929.001]
  • [Cites] Trends Microbiol. 2007 Oct;15(10):456-61 [17920274.001]
  • [Cites] Trends Cell Biol. 2007 Nov;17(11):555-62 [17949983.001]
  • (PMID = 19193236.001).
  • [ISSN] 1471-2180
  • [Journal-full-title] BMC microbiology
  • [ISO-abbreviation] BMC Microbiol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBS/E/F/00042291; United Kingdom / Biotechnology and Biological Sciences Research Council / / D20452; United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 0 / Chemotactic Factors
  • [Other-IDs] NLM/ PMC2672935
  •  go-up   go-down


27. Tabayashi K: [Comparison of therapeutic strategies for cardiovascular disease between Western countries and Japan]. Nihon Geka Gakkai Zasshi; 2008 Nov;109(6):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of therapeutic strategies for cardiovascular disease between Western countries and Japan].
  • A comparative review was performed to clarify the differences in therapeutic strategies and operative results in cardiovascular disease between Western countries and Japan, with the following results. (1) The operative results in the U.S.A. among patients with common cardiovascular diseases were almost the same as among those in Japan, except among those who underwent thoracic descending aortic and thoracoabdominal aortic repair. (2) The number of off-pump coronary artery bypass grafts performed comprises 20% to 30% of all coronary revascularization procedures in Western countries, while in Japan the number exceeds 60%. (3) Total endoscopic coronary artery bypass grafting and percutaneous aortic valve implantation can be performed safely but are currently restricted to only a few indications and are associated with several problems that require further improvement.
  • In these areas, Western countries are ahead of Japan. (4) Selective cerebral perfusion is a safer method of cerebral protection during aortic arch repair compared with retrograde cerebral perfusion and hypothermic circulatory arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068712.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Lesuisse E, Knight SA, Courel M, Santos R, Camadro JM, Dancis A: Genome-wide screen for genes with effects on distinct iron uptake activities in Saccharomyces cerevisiae. Genetics; 2005 Jan;169(1):107-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hierarchical clustering analysis grouped the data according to iron sources and according to mutant categories.
  • In the first analysis, siderophores grouped together with the exception of enterobactin, which grouped with iron salts, suggesting a reductive pathway of iron uptake for this siderophore.

  • MedlinePlus Health Information. consumer health - Iron.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • The Lens. Cited by Patents in .
  • Yeast Functional Genomics Database. Yeast Functional Genomics Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):33025-34 [10551871.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1917-29 [8756349.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):38061-70 [10608875.001]
  • [Cites] J Biol Chem. 2000 Apr 7;275(14):10709-15 [10744769.001]
  • [Cites] Biometals. 1999 Dec;12(4):301-6 [10816729.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16354-9 [10748025.001]
  • [Cites] Biometals. 2000 Mar;13(1):65-72 [10831226.001]
  • [Cites] Microbiology. 2001 Feb;147(Pt 2):289-98 [11158346.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):384-91 [11283612.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7762-8 [11112771.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):34221-6 [11448968.001]
  • [Cites] J Gen Microbiol. 1989 Feb;135(2):257-63 [11699493.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14322-7 [11734641.001]
  • [Cites] Microbiology. 2002 Jan;148(Pt 1):29-40 [11782496.001]
  • [Cites] Hum Mol Genet. 2002 May 15;11(11):1351-62 [12019217.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3632-42 [12110576.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):893-905 [12461556.001]
  • [Cites] Mol Microbiol. 2003 Mar;47(5):1185-97 [12603727.001]
  • [Cites] Hum Mol Genet. 2003 Apr 15;12(8):879-89 [12668611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10353-7 [12890866.001]
  • [Cites] Appl Microbiol Biotechnol. 2003 Sep;62(4):316-30 [12759789.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):247-54 [12868958.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45499-506 [12928433.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4322-9 [14594803.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):599-607 [14629196.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20850-7 [14998997.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(11):4848-57 [15143178.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1453-4 [14871861.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):29938-43 [15107423.001]
  • [Cites] FEBS Lett. 1988 Apr 11;231(1):253-8 [3282922.001]
  • [Cites] Mol Cell Biol. 1990 May;10(5):2294-301 [2183029.001]
  • [Cites] Methods Enzymol. 1991;194:398-405 [1706459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3869-73 [1570306.001]
  • [Cites] J Biol Chem. 1993 Jun 15;268(17):12749-57 [8509410.001]
  • [Cites] Cell. 1994 Jan 28;76(2):393-402 [8293472.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3065-73 [8164662.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32085-91 [7798202.001]
  • [Cites] EMBO J. 1995 Mar 15;14(6):1231-9 [7720713.001]
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):14240-4 [8662973.001]
  • [Cites] EMBO J. 1996 Jul 1;15(13):3377-84 [8670839.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):268-73 [9030748.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11770-7 [9115232.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13786-92 [9153234.001]
  • [Cites] Nature. 1997 Jul 10;388(6638):195-200 [9217162.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25787-93 [9325307.001]
  • [Cites] Yeast. 1997 Dec;13(15):1423-35 [9434348.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18389-93 [9660806.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Microbiology. 1998 Dec;144 ( Pt 12):3455-62 [9884238.001]
  • [Cites] J Biol Chem. 1995 Jun 9;270(23):13726-32 [7775427.001]
  • [Cites] Science. 1996 Mar 15;271(5255):1552-7 [8599111.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34294-300 [10567405.001]
  • (PMID = 15489514.001).
  • [ISSN] 0016-6731
  • [Journal-full-title] Genetics
  • [ISO-abbreviation] Genetics
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK053953; United States / NIDDK NIH HHS / DK / R37 DK053953; United States / NIDDK NIH HHS / DK / DK-53953
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Iron Chelating Agents; 0 / Saccharomyces cerevisiae Proteins; 0 / Siderophores; 28384-96-5 / Enterobactin; 4A0UG9NR9K / ferrioxamine B; E1UOL152H7 / Iron; EC 1.5.1.38 / FMN Reductase; EC 1.6.99.- / ferric citrate iron reductase; J06Y7MXW4D / Deferoxamine
  • [Other-IDs] NLM/ PMC1448889
  •  go-up   go-down


29. Wobst I, Schiffmann S, Birod K, Maier TJ, Schmidt R, Angioni C, Geisslinger G, Grösch S: Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem Pharmacol; 2008 Jul 1;76(1):62-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, in this study we show that DMC inhibits PGE(2) production in vitro in the low micromolar range in different cancer cell lines.
  • This effect can be at least partly explained by our findings that DMC inhibits microsomal prostaglandin E synthase-1 (mPGES-1) activity in a cell-free assay.
  • Moreover, it prevents mPGES-1 up-regulation after stimulation of HeLa cells with IL-1beta and TNFalpha.
  • Conversely, DMC has no effect on the expression levels of COX-1, COX-2, cytosolic PGES (cPGES) or mPGES-2 in these cells.
  • However, in the cell-free assay DMC inhibits mPGES-1 to a maximum of 65% only and concentrations needed for inhibition of mPGES-1 activity are about 10-fold higher than needed for inhibition of PGE(2) production in cell culture.
  • In cell culture experiments the anti-proliferative effect of DMC, measured by the WST-1 assay, seems not to be dependent on PGE(2) inhibition, as DMC was equally effective in unstimulated HeLa cells as well as in stimulated HeLa cells, and the addition of external PGE(2) did not reverse the anti-proliferative effect of DMC in HCA-7 cells.
  • [MeSH-minor] Blotting, Western. Cell Proliferation / drug effects. HeLa Cells. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508034.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2,5-dimethylcelecoxib; 0 / Prostaglandin Antagonists; 0 / Pyrazoles; 0 / Sulfonamides; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


30. Jha NK, Trudel M, Eising GP, Lange P, Al Sousi A, Al Mahmeed W, Khan JA, Saleh MA, Von Canal F, Misra VK, Augustin N: Inflammatory myofibroblastic tumor of the right atrium. Case Rep Med; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This report will help in better understanding and management of similar cases in terms of planning cannulation of femoral veins or application of total hypothermic circulatory arrest during cardiopulmonary bypass and prompt us to look for recurrence or metastasis during follow up using echocardiography and laboratory investigations.
  • The possibility of IMT should be kept in the differential diagnosis of cardiac tumors especially in children and adolescents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886029.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2945675
  •  go-up   go-down


31. Jin P, Wang E, Ren J, Childs R, Shin JW, Khuu H, Marincola FM, Stroncek DF: Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med; 2008;6:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis.
  • BACKGROUND: Mobilized-peripheral blood hematopoietic stem cells (HSCs) have been used for transplantation, immunotherapy, and cardiovascular regenerative medicine.
  • The HSCs cells mobilized by each agent may contain different subtypes and have different functions.
  • To characterize mobilized HSCs used for clinical applications, microRNA (miRNA) profiling and gene expression profiling were used to compare AMD3100-mobilized CD133+ cells from 4 subjects, AMD3100 plus G-CSF-mobilized CD133+ cells from 4 subjects and G-CSF-mobilized CD34+ cells from 5 subjects.
  • RESULTS: Hierarchical clustering of miRNAs separated HSCs from PBLs. miRNAs up-regulated in all HSCs included hematopoiesis-associated miRNA; miR-126, miR-10a, miR-221 and miR-17-92 cluster. miRNAs up-regulated in PBLs included miR-142-3p, -218, -21, and -379.
  • Hierarchical clustering analysis of miRNA expression separated the AMD3100-mobilized CD133+ cells from G-CSF-mobilized CD34+ cells.
  • Gene expression analysis of the HSCs naturally segregated samples according to mobilization and isolation protocol and cell differentiation status.
  • [MeSH-major] DNA, Complementary / metabolism. Hematopoietic Stem Cell Mobilization / methods. Hematopoietic Stem Cells / metabolism. MicroRNAs / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):4109-13 [1373894.001]
  • [Cites] Br J Haematol. 1994 Jul;87(3):609-13 [7527648.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2842-8 [7545476.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Blood. 2005 Dec 1;106(12):4002-8 [16105977.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):334-8 [16307419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18081-6 [16330772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83 [16549775.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):457-9 [10748532.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3581-6 [12097256.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2728-30 [12855591.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):72-9 [14675410.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1095-102 [15020611.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Blood. 2006 May 1;107(9):3772-8 [16439684.001]
  • [Cites] Exp Hematol. 2006 Aug;34(8):1052-9 [16863911.001]
  • [Cites] J Cell Biochem. 2006 Oct 15;99(3):690-705 [16888804.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Development. 2007 Jan;134(2):393-405 [17166922.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):492-501 [17273561.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):398-411 [17382247.001]
  • [Cites] Development. 2007 May;134(9):1703-12 [17395646.001]
  • [Cites] Retrovirology. 2007;4:5 [17442096.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1195-203 [17476349.001]
  • [Cites] Blood. 2007 May 15;109(10):4399-405 [17284533.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 22;358(1):12-7 [17475218.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Oncogene. 2007 Jun 14;26(28):4148-57 [17260024.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5699-707 [17575136.001]
  • [Cites] Circulation. 2007 Jun 26;115(25):3165-72 [17562958.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6092-9 [17616664.001]
  • [Cites] Congest Heart Fail. 2007 Jul-Aug;13(4):221-7 [17673875.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]
  • [Cites] J Transl Med. 2007;5:37 [17640360.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1224-32 [17889360.001]
  • [Cites] J Cell Biochem. 2008 Jun 1;104(3):805-17 [18189265.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):635-8 [8757135.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2033-42 [8822922.001]
  • [Cites] J Exp Med. 1997 Jan 6;185(1):111-20 [8996247.001]
  • [Cites] Transfus Med. 1997 Mar;7(1):19-24 [9089980.001]
  • [Cites] Blood. 1997 May 15;89(10):3522-8 [9160656.001]
  • [Cites] Blood. 1998 Jan 1;91(1):100-10 [9414273.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4523-30 [9616148.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1307-18 [15837815.001]
  • [Cites] J Cell Physiol. 2005 Jul;204(1):280-5 [15648093.001]
  • [Cites] Exp Hematol. 2005 Jun;33(6):713-8 [15911096.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1867-74 [15890685.001]
  • (PMID = 18647411.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / DNA, Complementary; 0 / Heterocyclic Compounds; 0 / MicroRNAs; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 155148-31-5 / JM 3100
  • [Other-IDs] NLM/ PMC2503968
  •  go-up   go-down


32. Zareef M, Innocenti A, Iqbal R, Zaidi JH, Arfan M, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozymes I and II with some 1,3,4-oxadiazole-thiols. J Enzyme Inhib Med Chem; 2006 Aug;21(4):351-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of these compounds have been investigated for the inhibition of three physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the human cytosolic hCA I and II, and the human, transmembrane, tumor-associated isozyme hCA IX.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059166.001).
  • [ISSN] 1475-6366
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbonic Anhydrase Inhibitors; 0 / Protein Isoforms; 0 / Sulfhydryl Compounds; EC 4.2.1.- / Carbonic Anhydrase I; EC 4.2.1.- / Carbonic Anhydrase II
  •  go-up   go-down


33. Bianco A, D'Ambra L, Bonfante P, Bianchi C, Magistrelli P, Berti P, Falco E: [Surgical timing in bleeding liver adenoma: case report]. G Chir; 2007 Oct;28(10):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical timing in bleeding liver adenoma: case report].
  • [Transliterated title] Timing chirurgico nell'adenoma epatico sanguinante: case report.
  • The diagnosis of liver adenoma, which etiopathogenesis most often involves a prolonged assumption of estrogen (90% of adenomas occurs in women after more than 5 years of estrogen therapy), always imposes a surgical resection.
  • Liver resection should be performed with appropriate selective endovascular embolization, considering that an inept emergency surgery may impose a greater risk ot the liver, exposing the patient to major risk of morbidity and mortality.
  • The authors relate their own experience about the therapeutic strategy and surgical timing in a case of bleeding liver adenoma.
  • [MeSH-major] Adenoma / surgery. Embolization, Therapeutic. Hemorrhage / surgery. Hepatectomy. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915055.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


34. Gasparri F, Ciavolella A, Galvani A: Cell-cycle inhibitor profiling by high-content analysis. Adv Exp Med Biol; 2007;604:137-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-cycle inhibitor profiling by high-content analysis.
  • The discovery of agents which disrupt cancer cell division by specifically targeting key components of the cell-cycle machinery represents a major focus of recent drug discovery efforts in Oncology.
  • The drug discovery process can be greatly enhanced by multiparametric cellular analysis which can assist in confirmation, often in a few multiplexed assays, of the mechanism of action (MOA) of compounds identified through biochemical screening or similar in vitro methods.
  • High-Content Analysis (HCA) is a technique based on automated microscopy which enables multiparametric analysis of fluorescent indicators to define cellular responses to compound treatment.
  • Several distinct fluorescence channels can be acquired and analyzed within a single measure in the same cell population.
  • Here we present a multiparametric HCA approach to characterize potential cell-cycle inhibitors in osteosarcoma U-2 OS adherent cell cultures.
  • This approach allows monitoring of compound-induced cell-cycle perturbations by analyzing specific cellular markers such as nuclear morphology, DNA content or histone H3 phosphorylation.
  • [MeSH-major] Cell Cycle / drug effects. Microscopy, Fluorescence / methods
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Apoptosis. Cell Line, Tumor. DNA Damage. DNA, Complementary / metabolism. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Histones / metabolism. Humans. Models, Biological. Oligonucleotide Array Sequence Analysis / methods. Phenotype

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695726.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Complementary; 0 / Histones
  • [Number-of-references] 25
  •  go-up   go-down


35. Sebag P, Tourasse C, Rouyer N, Lebas P, Dénier JF, Michenet P: [Value of vacuum assisted biopsies under sonography guidance: results from a multicentric study of 650 lesions]. J Radiol; 2006 Jan;87(1):29-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Place des macrobiopsies mammaires assistées par le vide sous guidage échographique: étude multi-centrique de 650 lésions.
  • Lesions were categorized, using the classification from Stavros, between "probably benign", "indeterminate", "probably malignant" and "malignant" Histology was validated only after review of the clinical and radiological data, as well as surgical data when available.
  • All benign cases were included in an on-going follow-up protocol.
  • RESULTS: We have identified 471 benign lesions and 179 malignant lesions.
  • Three cancers were diagnosed in the cases of "probably benign lesions" and in the cases of "probably malignant lesions" 18 (27%) were inflammatory disorders.
  • In 5 cases vacuum biopsy underestimated the pathology with regard to surgery: 2 cases of atypical duct hyperplasia (HCA) were in situ ductal carcinoma (DCIS) at surgery and 3 cases of DCIS were infiltrative ductal carcinoma (DCI) at surgery.
  • Specificity is excellent with no cancer detected so far among the patients with benign findings, under follow-up.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibroadenoma / pathology. Follow-Up Studies. Humans. Hyperplasia. Middle Aged. Minimally Invasive Surgical Procedures. Papilloma / pathology. Phyllodes Tumor / pathology. Retrospective Studies. Sensitivity and Specificity. Vacuum

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415777.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


36. Yekeler I, Ates A, Ozyazicioglu A, Balci AY, Erkut B, Erol MK: Time and risk analysis for acute type A aortic dissection surgery performed by hypothermic circulatory arrest, cerebral perfusion, and open distal aortic anastomosis. Heart Surg Forum; 2005;8(5):E337-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time and risk analysis for acute type A aortic dissection surgery performed by hypothermic circulatory arrest, cerebral perfusion, and open distal aortic anastomosis.
  • BACKGROUND: Hypothermic total circulatory arrest, retrograde or antegrade cerebral perfusion, and open distal anastomosis are important stages of surgical management and cerebral protection for acute type A dissections.
  • The diagnosis was based on clinical examination, telecardiography, transthoracic echocardiography, computerized tomography, and angiography.
  • Hypothermic total circulatory arrest, retrograde or antegrade cerebral perfusion and open distal anastomosis were used during the procedures.
  • Time to admission, durations of total circulatory arrest, cross-clamp, cardiopulmonary bypass, and intubation were longer, and postoperative blood loss was greater in patients who died during early postoperative period, although the differences did not reach statistical significance.
  • Duration of total circulatory arrest was longer in patients who developed neurological dysfunction compared to patients without this complication; this difference also did not reach statistical significance.
  • CONCLUSIONS: Total circulatory arrest, cerebral perfusion, and open distal anastomosis are reliable options in the surgical management of acute type A aortic dissections.
  • In the present study, although statistical significance could not be reached due to limited sample size, the time to admission, durations of total circulatory arrest, cross-clamp, and cardiopulmonary bypass, and the amount of postoperative chest output seem to influence postoperative survival.
  • [MeSH-minor] Acute Disease. Adult. Aged. Anastomosis, Surgical. Aorta / surgery. Cerebrovascular Circulation. Echocardiography. Female. Heart Arrest, Induced. Humans. Hypothermia, Induced. Male. Middle Aged. Reperfusion. Risk Assessment. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16099736.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kim HG: [Biliary cystic neoplasm: biliary cystadenoma and biliary cystadenocarcinoma]. Korean J Gastroenterol; 2006 Jan;47(1):5-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biliary cystic tumors, such as cystadenoma and cystadenocarcinoma, are rare cystic tumors of liver accounting for fewer than 5% of all intrahepatic cysts of biliary origin.
  • Most biliary cystic tumors arise from intrahepatic bile duct and 10-20% arise from extrahepatic bile duct like common hepatic duct, common bile duct, and gallbladder.
  • Over 80% of cystadenoma have dense mesenchymal stroma composed of dense spindle cells, like ovary.
  • The epithelial lining of cystadenocarcinoma exhibits cellular atypia, mitotic activity, and infiltrative growth, but part of lining epithelium retain the feature of cystadenoma, which support the adenoma-carcinoma sequence.
  • Biliary cystic tumor should be considered when a single or multilocular cystic lesion with papillary infoldings is detected in the liver by computed tomogram (CT) or ultrasound (US).
  • But tumor markers cannot distinguish cystadenocarcinoma from cystadenoma or both from other cystic lesions of liver.
  • Malignant cells are not usually recovered in patients with cystadenocarcinoma who underwent cystic fluid cytology before and during surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434863.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Number-of-references] 64
  •  go-up   go-down


38. Jho EH, Singhal N, Turner S: Degradation of hexachloroethane by Fenton's reagents. Water Sci Technol; 2008;58(11):2211-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of hydrogen peroxide (H2O2) concentrations on the degradation of hexachloroethane (HCA) in the absence and the presence of tetrachloroethene (PCE) by Fenton's reagent was investigated at pH 3 with 1 mM iron(II) and H2O2 concentrations ranging from 0.01 M to 2 M.
  • HCA degradation in the absence of PCE increased with increasing H2O2 concentration between 0.2 M and 2 M.
  • In the presence of PCE, HCA degradation was similar to that in the absence of PCE for H2O2 concentration up to 1 M, but significantly higher for 2 M H2O2.

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. Tetrachloroethylene .
  • Hazardous Substances Data Bank. HEXACHLOROETHANE .
  • Hazardous Substances Data Bank. ETHANE .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) IWA Publishing 2008.
  • (PMID = 19092198.001).
  • [ISSN] 0273-1223
  • [Journal-full-title] Water science and technology : a journal of the International Association on Water Pollution Research
  • [ISO-abbreviation] Water Sci. Technol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fenton's reagent; 0 / Hydrocarbons, Chlorinated; BBX060AN9V / Hydrogen Peroxide; E1UOL152H7 / Iron; G30K3QQT4J / hexachloroethane; L99N5N533T / Ethane; TJ904HH8SN / Tetrachloroethylene
  •  go-up   go-down


39. Kataoka H, Miyake M, Nishioka S, Matsumoto T, Saito K, Mitani K: Formation of protein adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in cooked foods. Mol Nutr Food Res; 2010 Jul;54(7):1039-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterocyclic amines (HCAs) are mutagenic and carcinogenic compounds found in cooked meat and fish.
  • Although HCAs are known to form adducts with protein after metabolic activation, adduct formation during cooking has not been elucidated.
  • A new adduct peak including [M+H](+) (m/z=225) of PhIP as a fragment ion was detected in the high molecular weight fraction of heat-treated protein by LC-MS analysis.
  • These results suggest that food-borne protein adducts of HCAs may influence human HCA exposure and carcinogenic risk.
  • [MeSH-major] Carcinogens / chemistry. Food Contamination. Hot Temperature / adverse effects. Imidazoles / analysis. Imidazoles / chemistry. Mutagens / chemistry. Proteins / chemistry
  • [MeSH-minor] Amino Acids / chemistry. Animals. Chromatography, Gas / methods. Chromatography, High Pressure Liquid. Fishes. Hydrolysis. Meat / analysis. Microchemistry / methods. Molecular Weight. Seafood / analysis. Serum Albumin, Bovine / chemistry. Spectrometry, Mass, Electrospray Ionization. Tandem Mass Spectrometry. Time Factors

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • Hazardous Substances Data Bank. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960457.001).
  • [ISSN] 1613-4133
  • [Journal-full-title] Molecular nutrition & food research
  • [ISO-abbreviation] Mol Nutr Food Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Carcinogens; 0 / Imidazoles; 0 / Mutagens; 0 / Proteins; 0 / Serum Albumin, Bovine; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  •  go-up   go-down


40. Vaughan P: The 'year of the HCA'. Nurs Manag (Harrow); 2008 Feb 01;14(9):8-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 'year of the HCA'.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27351964.001).
  • [ISSN] 1354-5760
  • [Journal-full-title] Nursing management (Harrow, London, England : 1994)
  • [ISO-abbreviation] Nurs Manag (Harrow)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Lai YL, Yamaguchi M: Phytocomponent p-hydroxycinnamic acid inhibits osteoclast-like cell formation in mouse bone marrow cultures. Int J Mol Med; 2007 Jan;19(1):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phytocomponent p-hydroxycinnamic acid inhibits osteoclast-like cell formation in mouse bone marrow cultures.
  • The phytocomponent p-hydroxycinnamic acid (HCA) has been shown to have inhibitory effects on bone-resorbing factor-stimulated bone resorption in rat femoral tissues in vitro.
  • The effects of HCA on osteoclast-like cell formation in mouse bone marrow cultures in vitro were investigated.
  • The bone marrow cells were cultured for 7 days in alpha-minimal essential medium containing a bone-resorbing agent [parathyroid hormone (1-34)] (PTH), prostaglandin E2 (PGE2), or tumor necrosis factor-alpha (TNF-alpha) in effective concentrations.
  • Osteoclast-like cell formation was estimated by staining for tartrate-resistant acid phosphatase, a marker enzyme of osteoclasts.
  • The presence of PTH (10(-7) M), PGE2 (10(-5) M), or TNF-alpha (10 ng/ml) induced a remarkable increase in osteoclast-like multinucleated cells.
  • These increases were significantly inhibited in the presence of HCA (10(-8)-10(-5) M).
  • HCA (10(-6) or 10(-5) M) significantly inhibited osteoclast-like cell formation induced by dibutyryl cyclic adenosine monophosphate (10(-5) M) or phorbol 12-myristate 13-acetate (10(-6) M), an activator of protein kinase C.
  • Also, HCA (10(-8)-10(-5) M) had a significant inhibitory effect on osteoclast-like cell formation induced by the receptor activator of NF-kappaB ligand (RANKL) (10 ng/ml) in the presence of macrophage colony-stimulating factor (M-CSF) (10 ng/ml).
  • The inhibitory effect of HCA (10(-6) or 10(-5) M) on RANKL plus M-CSF-induced osteoclast-like cell formation was not observed in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis in the transcriptional process, or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (10(-6) M), an inhibitor of transcription.
  • This study demonstrates that HCA has a potent inhibitory effect on osteoclast-like cell formation in mouse bone marrow cultures.
  • The inhibitory action of HCA may partly involve a newly synthesized protein component which is related to RANKL stimulation in osteoclastogenesis.
  • [MeSH-major] Bone Marrow Cells / drug effects. Coumaric Acids / pharmacology. Osteoclasts / drug effects
  • [MeSH-minor] Animals. Cell Differentiation. Cytokines / pharmacology. Drug Interactions. Intracellular Signaling Peptides and Proteins / metabolism. Male. Mice. RANK Ligand / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143556.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Coumaric Acids; 0 / Cytokines; 0 / Intracellular Signaling Peptides and Proteins; 0 / RANK Ligand; 0 / bone resorption factor; IBS9D1EU3J / 4-coumaric acid
  •  go-up   go-down


42. McGregor D: Methyl tertiary-butyl ether: studies for potential human health hazards. Crit Rev Toxicol; 2006 Apr;36(4):319-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In carcinogenicity studies of MTBE, TBA, and methanol (included as an endogenous precursor of formaldehyde, without the presence of TBA), some increases in tumor incidence have been observed, but consistency of outcome was lacking and even some degree of replication was observed in only three cases, none of which had human relevance: alpha(2u)-globulin nephropathy-related renal tubule cell adenoma in male rats; Leydig-cell adenoma in male rats, but not in mice, which provide the better model of the human disease; and B-cell-derived lymphoma/leukemia of doubtful pathogenesis that arose mainly in lungs of orally dosed female rats.
  • In addition, hepatocellular adenomas were significantly higher in female CD-1 mice and thyroid follicular-cell adenomas were increased in female B6C3F1 mice treated with TBA, but these results lack any independent confirmation, which would have been possible from a number of other studies.

  • Hazardous Substances Data Bank. Methyl t-butyl ether .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809102.001).
  • [ISSN] 1040-8444
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Hazardous Substances; 0 / Methyl Ethers; 29I4YB3S89 / methyl tert-butyl ether
  • [Number-of-references] 232
  •  go-up   go-down


43. Lameira J, Medeiros IG, Reis M, Santos AS, Alves CN: Structure-activity relationship study of flavone compounds with anti-HIV-1 integrase activity: a density functional theory study. Bioorg Med Chem; 2006 Nov 1;14(21):7105-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we employed density functional theory (DFT) using the B3LYP hybrid functional to calculate a set of molecular properties for 32 flavonoid compounds with anti-HIV-1 IN activity.
  • The stepwise discriminant analysis (SDA), principal component analysis (PCA) and hierarchical cluster analysis (HCA) methods were employed to reduce dimensionality and investigate possible relationship between the calculated properties and the anti-HIV-1 IN activity.
  • These analyses showed that the molecular hydrophobicity (ClogP), charge on atom 11 and electrophilic index (omega) are responsible for the separation between anti-HIV-1 IN active and inactive compounds.
  • [MeSH-minor] Cluster Analysis. Discriminant Analysis. Static Electricity. Structure-Activity Relationship

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890444.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Flavones; 0 / HIV Integrase Inhibitors
  •  go-up   go-down


44. Frison G, Ohanessian G: Metal-histidine-glutamate as a regulator of enzymatic cycles: a case study of carbonic anhydrase. Phys Chem Chem Phys; 2009 Jan 14;11(2):374-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We study this situation in Human Carbonic Anhydrase II (HCA II) in which one of the three histidines bound to zinc (His119) interacts also with a glutamate residue (Glu117).
  • We show that the carboxylate group of Glu117 behaves only as a hydrogen bond acceptor in the hydroxy form of HCA II.
  • On the other hand, our results suggest that Glu117 could exist either as a hydrogen bond acceptor or as a proton acceptor in the aqua form of HCA II, the two isomers having almost the same thermodynamic stability.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19088994.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Metals; 3KX376GY7L / Glutamic Acid; 4QD397987E / Histidine; EC 4.2.1.- / Carbonic Anhydrase II
  •  go-up   go-down


45. Sato A, Terata K, Miura H, Toyama K, Loberiza FR Jr, Hatoum OA, Saito T, Sakuma I, Gutterman DD: Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol Heart Circ Physiol; 2005 Apr;288(4):H1633-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease.
  • We examined the mechanism of adenosine-induced vasodilation in coronary arterioles from patients with heart disease.
  • Human coronary arterioles (HCAs) were dissected from pieces of the atrial appendage obtained at the time of cardiac surgery and cannulated for the measurement of internal diameter with videomicroscopy.
  • Moreover, dilation to A(2a) receptor activation with 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamido-adenosine hydrochloride was reduced by the A(1) receptor agonist (2S)-N(6)-(2-endo-norbornyl)adenosine.
  • In conclusion, adenosine endothelium independently dilates HCAs from patients with heart disease through a receptor-mediated mechanism that involves the activation of intermediate-conductance K(Ca) channels via an AC signaling pathway.

  • Genetic Alliance. consumer health - Heart Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Adenosine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772334.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Potassium Channel Blockers; 0 / Potassium Channels; 0 / Receptor, Adenosine A2A; 0 / Vasodilator Agents; K72T3FS567 / Adenosine
  •  go-up   go-down


46. Tsagakis K, Pacini D, Di Bartolomeo R, Gorlitzer M, Weiss G, Grabenwoger M, Mestres CA, Benedik J, Cerny S, Jakob H: Multicenter early experience with extended aortic repair in acute aortic dissection: is simultaneous descending stent grafting justified? J Thorac Cardiovasc Surg; 2010 Dec;140(6 Suppl):S116-20; discussion S142-S146
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the early results of a multicenter study using a hybrid stent graft prosthesis.
  • Hypothermic circulatory arrest and selective cerebral perfusion were routinely used.
  • CONCLUSIONS: Extended thoracic aortic repair of acute aortic dissection with a hybrid stent graft is feasible at acceptable early mortality and promotes false lumen thrombosis around the stent graft and below.
  • [MeSH-minor] Acute Disease. Adult. Aged. Aortography / methods. Cerebrovascular Circulation. Circulatory Arrest, Deep Hypothermia Induced. Feasibility Studies. Female. Hospital Mortality. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Perfusion / methods. Prosthesis Design. Registries. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • (PMID = 21092776.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


47. Kawaguchi K, Honda M, Yamashita T, Shirota Y, Kaneko S: Differential gene alteration among hepatoma cell lines demonstrated by cDNA microarray-based comparative genomic hybridization. Biochem Biophys Res Commun; 2005 Apr 1;329(1):370-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene alteration among hepatoma cell lines demonstrated by cDNA microarray-based comparative genomic hybridization.
  • We assayed chromosomal abnormalities in hepatoma cell lines using the microarray-based comparative genomic hybridization (array-CGH) method and investigated the relationship between genomic copy number alterations and expression profiles in these hepatoma cell lines.
  • We modified a cDNA array-CGH assay to compare genomic DNAs from seven hepatoma cell lines, as well as DNA from two non-hepatoma cell lines and from normal cells.
  • We predominantly found alterations of apoptosis-related genes in Hep3B and HepG2, cell adhesion and receptor molecules in HLE, and cytokine-related genes in PLC/PRF/5.
  • Hierarchical clustering analysis showed that the expression of these genes allows differentiation between alpha-fetoprotein (AFP)-producing and AFP-negative cell lines. cDNA array-CGH is a sensitive method that can be used to detect alterations in genomic copy number in tumor cells.
  • Differences in DNA copy alterations between AFP-producing and AFP-negative cells may lead to differential gene expression and may be related to the phenotype of these cells.
  • [MeSH-major] Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Apoptosis. Blotting, Southern. Carcinoma, Hepatocellular / metabolism. Cell Adhesion. Cell Line, Tumor. Chromosome Mapping. Cluster Analysis. DNA, Complementary / metabolism. Gene Deletion. Humans. Phenotype. Protein Binding. RNA, Messenger / metabolism. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721316.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Messenger; 0 / alpha-Fetoproteins
  •  go-up   go-down


48. Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, Regan JW, Meuillet E, Nelson MA: The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res; 2007 Aug 15;313(14):2969-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells.
  • Accumulating evidence indicates that elevated levels of prostaglandin E(2) (PGE(2)) can increase intestinal epithelial cell proliferation, and thus play a role in colorectal tumorigenesis.
  • Increased phosphorylation of extracellular regulated kinases (ERK1/2) is required for PGE(2) to stimulate cell proliferation of human colon cancer cells.
  • We provide evidence that L-161,982, a selective EP4 receptor antagonist, completely blocks PGE(2)-induced ERK phosphorylation and cell proliferation of HCA-7 cells.
  • PGE(2) treatment induces phosphorylation of cyclic AMP response element binding protein (CREB) at Ser133 residue and CRE-mediated luciferase activity in HCA-7 cells.
  • Studies with dominant-negative CREB mutant (ACREB) provide clear evidence for the involvement of CREB in PGE(2) driven egr-1 transcription in HCA-7 cells.
  • In conclusion, this study reveals that egr-1 is a target gene of PGE(2) in HCA-7 cells and is regulated via the newly identified EP4/ERK/CREB pathway.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3106-13 [16540660.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):104-19 [16859832.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9665-72 [17018624.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5093-6 [10537280.001]
  • [Cites] DNA Seq. 2000;10(6):429-32 [10826704.001]
  • [Cites] Annu Rev Biochem. 1999;68:821-61 [10872467.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Mol Pharmacol. 2001 Jul;60(1):36-41 [11408598.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):28-32 [11782353.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):403-8 [11809688.001]
  • [Cites] Nat Med. 2002 Mar;8(3):289-93 [11875501.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28601-8 [12034740.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2650-8 [12239181.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12151-6 [12566441.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):985-90 [12771044.001]
  • [Cites] FASEB J. 2003 Sep;17(12):1640-7 [12958170.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35451-7 [12824187.001]
  • [Cites] Exp Cell Res. 2003 Oct 1;289(2):265-74 [14499627.001]
  • [Cites] Life Sci. 2003 Dec 5;74(2-3):143-53 [14607241.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29797-804 [15123663.001]
  • [Cites] Gut. 2004 Aug;53(8):1151-8 [15247185.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):1031-9 [15299086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14895-900 [15469929.001]
  • [Cites] J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12 [2359136.001]
  • [Cites] Dis Colon Rectum. 1991 Jul;34(7):572-6 [2055143.001]
  • [Cites] J Lab Clin Med. 1993 Nov;122(5):518-23 [8228569.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Biochem Pharmacol. 1995 Nov 9;50(10):1731-3 [7503778.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1259-62 [8613017.001]
  • [Cites] Biochemistry. 1996 Jun 4;35(22):7159-64 [8679543.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):967-77 [9447994.001]
  • [Cites] Dig Dis Sci. 1998 Feb;43(2):311-6 [9512123.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Sep;286(3):1420-6 [9732406.001]
  • [Cites] J Cell Biochem. 2004 Nov 15;93(5):1063-74 [15449318.001]
  • [Cites] J Clin Invest. 2004 Dec;114(11):1676-85 [15578100.001]
  • [Cites] EMBO J. 2005 Jan 12;24(1):128-37 [15616591.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):353-7 [15564292.001]
  • [Cites] J Biol Chem. 2005 Feb 25;280(8):6676-81 [15615708.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9536-46 [15640148.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1822-9 [15753380.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2111-7 [15626689.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9934-42 [16267018.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jun;290(6):F1534-42 [16396944.001]
  • (PMID = 17631291.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097383-02; United States / NCI NIH HHS / CA / R01 CA097383; United States / NCI NIH HHS / CA / CA 097383; United States / NCI NIH HHS / CA / R01 CA097383-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / L-161982; 0 / PTGER4 protein, human; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP4 Subtype; 0 / Thiophenes; 0 / Triazoles; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ NIHMS28489; NLM/ PMC2706013
  •  go-up   go-down


49. Yuan SM, Tager S: Acute onset of chronic aortic dissection presenting as abdominal pain. Kardiol Pol; 2009 Feb;67(2):168-71; discussion 172
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A prompt diagnosis was made and urgent surgery was carried out successfully under profound hypothermic circulatory arrest.
  • The awareness of possible aortic dissection is the key point leading to an early diagnosis in patients with atypical presentations.
  • [MeSH-major] Aneurysm, Dissecting / diagnosis. Aortic Aneurysm / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Chronic Disease. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288380.001).
  • [ISSN] 0022-9032
  • [Journal-full-title] Kardiologia polska
  • [ISO-abbreviation] Kardiol Pol
  • [Language] eng; pol
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


50. Soga M, Hashimoto S, Kishimoto Y, Hirasawa T, Makino S, Inagaki S: Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene. Exp Anim; 2010;59(4):407-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene.
  • In order to examine the influence of obesity on metabolic disorder and liver pathogenesis of the Fatty Liver Shionogi (FLS) mouse, which develops hereditary fatty liver and spontaneous liver tumors, we established a new congenic strain named FLS-Lep(ob).
  • The steatohepatitis-like lesions including the multifocal mononuclear cell infiltration and clusters of foamy cells were observed earlier in FLS-Lep(ob)/ Lep(ob) mice than in FLS mice.
  • B6-Lep(ob)/Lep(ob) mice did not show hepatic inflammatory change.
  • Furthermore, FLS-Lep(ob)/Lep(ob) mice developed multiple hepatic tumors including hepatocellular adenomas and carcinomas following steatohepatitis.
  • In conclusion, the FLS-Lep(ob)/Lep(ob) mice developed steatohepatitis and hepatic tumors following hepatic steatosis.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660987.001).
  • [ISSN] 1881-7122
  • [Journal-full-title] Experimental animals
  • [ISO-abbreviation] Exp. Anim.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipids; 0 / RNA, Messenger
  •  go-up   go-down


51. Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer; 2006 Nov 20;95(10):1419-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other members of this family are expressed mainly in haematopoietic cells, whereas SASH1 shows ubiquitous expression.
  • Moreover, nine benign adenomas and 10 liver metastases were analysed.
  • Expression levels of SASH1 were strongly and significantly reduced in colon cancer of UICC stage II, III, and IV, as well as in liver metastases.
  • Moreover, SASH1 was also found to be downregulated on protein levels by immunoblot analysis.
  • However, SASH1 expression was not significantly deregulated in precancerous adenomas and in earlier stage lesions (UICC I).
  • Downregulation of SASH1 expression was correlated with the formation of metachronous distant metastasis, and multivariate analysis identified SASH1 downregulation as an independent negative prognostic parameter for patient survival.
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Colon / metabolism. Colon / pathology. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Jul 30;1520(1):89-93 [11470164.001]
  • [Cites] Cell Immunol. 2005 May;235(1):46-55 [16137664.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5373-7 [11536050.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 19;288(1):137-41 [11594764.001]
  • [Cites] Nat Struct Biol. 2002 Jun;9(6):453-7 [11992127.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2972-83 [12771949.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):369-80 [12800148.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Fam Cancer. 2004;3(2):93-100 [15340259.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):737-47 [15381729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nature. 1995 Feb 16;373(6515):573-80 [7531822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9646-60 [16227612.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):4173-82 [11483520.001]
  • (PMID = 17088907.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / SASH1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2360597
  •  go-up   go-down


52. Vallotton P, Lagerstrom R, Sun C, Buckley M, Wang D, De Silva M, Tan SS, Gunnersen JM: Automated analysis of neurite branching in cultured cortical neurons using HCA-Vision. Cytometry A; 2007 Oct;71(10):889-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated analysis of neurite branching in cultured cortical neurons using HCA-Vision.
  • We have developed fast, sensitive, and reliable algorithms for the purpose of detecting and analyzing neurites in cell cultures, and we have integrated them in software called HCA-Vision, suitable for the research environment.
  • We validate the software on images of cortical neurons by comparing results obtained using HCA-Vision with those obtained using an established semi-automated tracing solution (NeuronJ).
  • HCA-Vision delivered considerable speed benefits and reliable traces.
  • [MeSH-minor] Animals. Cells, Cultured. Image Processing, Computer-Assisted. Mice. Mice, Knockout

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868085.001).
  • [ISSN] 1552-4922
  • [Journal-full-title] Cytometry. Part A : the journal of the International Society for Analytical Cytology
  • [ISO-abbreviation] Cytometry A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Akiskal HS, Akiskal KK, Lancrenon S, Hantouche EG, Fraud JP, Gury C, Allilaire JF: Validating the bipolar spectrum in the French National EPIDEP Study: overview of the phenomenology and relative prevalence of its clinical prototypes. J Affect Disord; 2006 Dec;96(3):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Measures tapping into this spectrum included the Hypomania Checklist (HCA), the cyclothymic (CT), depressive (DT) and hyperthymic (HT) temperament scales.
  • <<Strict UP>> was thereby limited to an exclusion diagnosis for the remainder of MDE.
  • [MeSH-major] Bipolar Disorder

  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824616.001).
  • [ISSN] 0165-0327
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Winum JY, Innocenti A, Scozzafava A, Montero JL, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isoforms I and II and transmembrane, tumor-associated isoforms IX and XII with boronic acids. Bioorg Med Chem; 2009 May 15;17(10):3649-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of aromatic, arylalkenyl- and arylalkyl boronic acids were assayed as inhibitors of four physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isoforms, the cytosolic human (h) hCA I and II, and the transmembrane, tumor-associated hCA IX and XII.
  • The best hCA I and II inhibitor was biphenyl boronic acid with, a K(I) of 3.7-4.5 microM, whereas the remaining derivatives showed inhibition constants in the range of 6.0-1560 microM for hCA I and of 6.0-1050 microM for hCA II, respectively. hCA IX and XII were effectively inhibited by most of the aromatic boronic acids (K(I)s of 7.6-12.3 microM) whereas the arylalkenyl and aryl-alkyl derivatives generally showed weaker inhibitory properties (K(I)s of 34-531 microM).
  • This study proves that the B(OH)(2) moiety represents a new zinc-binding group for the generation of effective CA inhibitors targeting isoforms with medicinal chemistry applications.
  • The boronic acids probably bind to the Zn(II) ion within the CA active site leading to a tetrahedral geometry of the metal ion and of the B(III) derivative.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375921.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Boronic Acids; 0 / Carbonic Anhydrase Inhibitors; EC 4.2.1.- / Carbonic Anhydrase I; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase XII; J41CSQ7QDS / Zinc
  •  go-up   go-down


55. Chen YC, Hsu RB: Aortic surgery requiring hypothermic circulatory arrest in octogenarians. J Formos Med Assoc; 2008 May;107(5):412-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortic surgery requiring hypothermic circulatory arrest in octogenarians.
  • BACKGROUND: Recent improvements in the outcomes of cardiovascular operation in octogenarians have resulted in an increase in the number of referrals of elderly patients for aortic surgery requiring hypothermic circulatory arrest.
  • RESULTS: Between 2000 and 2007, 12 octogenarians with aortic aneurysms underwent surgery requiring hypothermic circulatory arrest.
  • Diagnoses of aortic disease included acute type A aortic dissection in seven patients and degenerative thoracic aneurysm in five.
  • The median duration of hypothermic circulatory arrest was 50 minutes (range, 15-84 minutes).
  • Method of brain protection during hypothermia was selective antegrade cerebral perfusion in five patients, retrograde cerebral perfusion in two, and arrest alone in five.
  • CONCLUSION: Although postoperative complications were common, the clinical outcome of aortic surgery requiring hypothermic circulatory arrest was acceptable.

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492626.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


56. Carvajal-Zarrabal O, Waliszewski SM, Barradas-Dermitz DM, Orta-Flores Z, Hayward-Jones PM, Nolasco-Hipólito C, Angulo-Guerrero O, Sánchez-Ricaño R, Infanzón RM, Trujillo PR: The consumption of Hibiscus sabdariffa dried calyx ethanolic extract reduced lipid profile in rats. Plant Foods Hum Nutr; 2005 Dec;60(4):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A hypothesis of hibiscus acid racemization, (+)-HCA to (-)-HCA, mediated by intestinal flora enzymes possibly explains the significant triacylglycerol decrease in all experimental groups.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395625.001).
  • [ISSN] 0921-9668
  • [Journal-full-title] Plant foods for human nutrition (Dordrecht, Netherlands)
  • [ISO-abbreviation] Plant Foods Hum Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cholesterol, LDL; 0 / Lipids; 0 / Plant Extracts; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


57. Tochii M, Ando M, Takagi Y, Yamashita M, Hoshino R, Akita K: Left axillary arterial perfusion for cerebrospinal protection in proximal descending aortic aneurysm. Gen Thorac Cardiovasc Surg; 2008 Dec;56(12):589-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aneurysm of the descending aorta was replaced using an open proximal technique with hypothermic circulatory arrest.
  • [MeSH-minor] Aged. Cerebrovascular Disorders / etiology. Cerebrovascular Disorders / prevention & control. Circulatory Arrest, Deep Hypothermia Induced. Humans. Male. Regional Blood Flow. Spinal Cord Ischemia / etiology. Spinal Cord Ischemia / prevention & control. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vasc Surg. 2000 Jul;32(1):160-70 [10876219.001]
  • [Cites] J Vasc Surg. 2002 Jan;35(1):30-7 [11802130.001]
  • [Cites] Ann Thorac Surg. 2000 Jul;70(1):311-3 [10921741.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Nov;24(5):817-24 [14583316.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):481-6 [11515886.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 May;23(5):771-5; discussion 775 [12754031.001]
  • (PMID = 19085051.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Mantone J: HCA hits gain-sharing hurdle. Vendor objects to comments on usage levels. Mod Healthc; 2006 Feb 13;36(7):12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA hits gain-sharing hurdle. Vendor objects to comments on usage levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515059.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


59. Alterio V, Vitale RM, Monti SM, Pedone C, Scozzafava A, Cecchi A, De Simone G, Supuran CT: Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc; 2006 Jun 28;128(25):8329-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The X-ray crystal structure of the fluorescent antitumor sulfonamide carbonic anhydrase (CA, EC, 4.2.1.1) inhibitor (4-sulfamoylphenylethyl)thioureido fluorescein (1) in complex with the cytosolic isoform hCA II is reported, together with a modeling study of the adduct of 1 with the tumor-associated isoform hCA IX.
  • Its binding to hCA II is similar to that of other benzesulfonamides, with the ionized sulfonamide coordinated to the Zn2+ ion within the enzyme active site, and also participating in a network of hydrogen bonds with residues Thr199 and Glu106.
  • All these interactions were preserved in the hCA IX-1 adduct, but the carbonyl moiety of the fluorescein tail of 1 participates in a strong hydrogen bond with the guanidine moiety of Arg130, an amino acid characteristic of the hCA IX active site.
  • This may account for the roughly 2 times higher affinity of 1 for hCA IX over hCA II and may explain why in vivo the compound specifically accumulates only in hypoxic tumors overexpressing CA IX and not in the normal tissues.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOUREA .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787097.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / (4-sulfamoylphenylethyl)thioureido fluorescein; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Carbonic Anhydrase Inhibitors; 0 / Fluoresceins; 0 / Isoenzymes; 0 / Sulfonamides; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; GYV9AM2QAG / Thiourea
  •  go-up   go-down


60. Gitto R, Agnello S, Ferro S, Vullo D, Supuran CT, Chimirri A: Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors. ChemMedChem; 2010 Jun 7;5(6):823-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349499.001).
  • [ISSN] 1860-7187
  • [Journal-full-title] ChemMedChem
  • [ISO-abbreviation] ChemMedChem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Protein Isoforms; 0 / Sulfonamides; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase VI
  •  go-up   go-down


61. De Felice C, Del Vecchio A, Criscuolo M, Lozupone A, Parrini S, Latini G: Early postnatal changes in the perfusion index in term newborns with subclinical chorioamnionitis. Arch Dis Child Fetal Neonatal Ed; 2005 Sep;90(5):F411-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chorioamnionitis (HCA) in term newborns is often subclinical and associated with neonatal morbidity and mortality.
  • OBJECTIVE: To assess the value of the pulse oximetry perfusion index (PI) in the early prediction of subclinical HCA in term newborns.
  • METHODS: PI cut-off values were first identified in 51 term newborns with HCA and 115 matched controls, retrospectively categorised on the basis of placental histology (study phase 1).
  • RESULTS: In study phase 1, newborns with HCA had lower PI one and five minutes (p<0.0001) after delivery, lower one minute Apgar score (p = 0.017), lower cord blood base excess (p = 0.0001), together with higher rates of admission to neonatal intensive care unit (p = 0.0001) and endotracheal intubation (p = 0.017), and higher SNAP-PE (p<0.0001) and NTISS (p<0.0001) scores than those without HCA.
  • In the prospective validation phase of the study, the PI cut-off values generated (one minute < or =1.74, five minutes < or =2.18) showed 100% sensitivity, 99.4% specificity, 93.7% positive predictive value, and 100% negative predictive value in identifying subclinical HCA.
  • Early identification of HCA was associated with a decreased rate of admission to intensive care (p = 0.012), as well as lower initial illness severity (p< or =0.0001) and therapeutic intensity (p = 0.0006) than the newborns with HCA in phase 1.
  • CONCLUSION: These findings suggest that early PI monitoring is helpful in identifying HCA in term newborns.
  • [MeSH-major] Chorioamnionitis / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1999 Aug;94(2):274-8 [10432142.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jul;179(1):194-202 [9704787.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1121-8 [11014581.001]
  • [Cites] Am J Obstet Gynecol. 2000 Nov;183(5):1094-9 [11084547.001]
  • [Cites] J Pediatr. 2001 Jan;138(1):101-4 [11148520.001]
  • [Cites] Biol Neonate. 2001;79(3-4):201-4 [11275651.001]
  • [Cites] Anesth Analg. 2002 Jan;94(1 Suppl):S1-3 [11900029.001]
  • [Cites] Ment Retard Dev Disabil Res Rev. 2002;8(1):46-50 [11921386.001]
  • [Cites] Curr Opin Infect Dis. 2002 Jun;15(3):301-6 [12015466.001]
  • [Cites] Crit Care Med. 2002 Jun;30(6):1210-3 [12072670.001]
  • [Cites] Eur J Pediatr. 2002 Oct;161(10):561-2 [12297906.001]
  • [Cites] Pediatrics. 2002 Oct;110(4):673-80 [12359779.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):169-83 [12385841.001]
  • [Cites] Clin Perinatol. 2002 Dec;29(4):603-21 [12516738.001]
  • [Cites] JAMA. 2003 Nov 26;290(20):2677-84 [14645309.001]
  • [Cites] Eur J Pediatr. 2004 Sep;163(9):550-4 [15241686.001]
  • [Cites] Pediatr Res. 1992 Jun;31(6):596-600 [1635822.001]
  • [Cites] Pediatrics. 1992 Oct;90(4):561-7 [1408510.001]
  • [Cites] Pediatrics. 1993 May;91(5):969-75 [8474818.001]
  • [Cites] Acta Paediatr. 1994 Aug;83(8):808-11 [7981555.001]
  • [Cites] J Reprod Med. 1998 Apr;43(4):397-400 [9583075.001]
  • [Cites] J Perinat Med. 2004;32(6):535-7 [15576278.001]
  • (PMID = 15863488.001).
  • [ISSN] 1359-2998
  • [Journal-full-title] Archives of disease in childhood. Fetal and neonatal edition
  • [ISO-abbreviation] Arch. Dis. Child. Fetal Neonatal Ed.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1721936
  •  go-up   go-down


62. Cai YR, Gong L, Teng XY, Zhang HT, Wang CF, Wei GL, Guo L, Ding F, Liu ZH, Pan QJ, Su Q: Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma. World J Gastroenterol; 2009 Oct 7;15(37):4695-708
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and carcinoma.
  • Twelve hepatocellular adenomas (HCAs) and 22 hepatocellular carcinomas (HCCs) were used as references.
  • An X-chromosome inactivation assay was employed to describe their clonality status.
  • RESULTS: Nodules of altered hepatocytes (NAH), the putative precursors of HCA and HCC, were found in all the FNH lesions.
  • In contrast, monoclonality was demonstrated in all the eight HCAs and in four of the HCCs from females, and allelic imbalances were found in the HCAs (9/9) and HCCs (15/18), with chromosomal arms 11p, 13q and 17p affected in the former, and 6q, 8p, 11p, 16q and 17p affected in the latter lesions in high frequencies (> or = 30%).
  • CONCLUSION: FNH, as a whole, is polyclonal, but some of the NAH lesions derived from it are already neoplastic and harbor similar allelic imbalances as HCAs.
  • [MeSH-major] Adenoma, Liver Cell / genetics. Carcinoma, Hepatocellular / genetics. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / genetics. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Alleles. Clone Cells. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. X Chromosome Inactivation. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2000 Apr;462(2-3):365-80 [10767646.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5988-96 [18632655.001]
  • [Cites] J Pathol. 2001 Jan;193(1):27-32 [11169512.001]
  • [Cites] Virchows Arch. 2001 Apr;438(4):408-11 [11355178.001]
  • [Cites] Hepatology. 2001 Jun;33(6):1415-24 [11391530.001]
  • [Cites] Am J Obstet Gynecol. 2002 Feb;186(2):195-7 [11854634.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3179-85 [12115350.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2266-72 [12114430.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1441-54 [10584697.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1730-4 [10674021.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):560-4 [10702207.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):38-44 [10738301.001]
  • [Cites] Int J Exp Pathol. 2000 Apr;81(2):89-116 [10762440.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Oct;35(2):138-43 [12203777.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):927-35 [12297840.001]
  • [Cites] J Gastroenterol. 2002;37(10):849-53 [12424570.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):265-71 [12579998.001]
  • [Cites] Toxicol Pathol. 2003 Jan-Feb;31(1):126-33 [12597457.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):651-9 [12612904.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Apr;18(4):430-6 [12653892.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1323-9 [15131793.001]
  • [Cites] Semin Liver Dis. 1981 May;1(2):116-28 [6287645.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2197-205 [6303546.001]
  • [Cites] Hepatology. 1985 Nov-Dec;5(6):1194-200 [4065824.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6594-7 [1423305.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1089-96 [8644851.001]
  • [Cites] Biotechniques. 1997 Sep;23(3):504-11 [9298224.001]
  • [Cites] Clin Nucl Med. 1997 Sep;22(9):587-90 [9298289.001]
  • [Cites] Hepatology. 1997 Oct;26(4):891-5 [9328310.001]
  • [Cites] Virchows Arch. 1997 Dec;431(6):391-406 [9428927.001]
  • [Cites] Am J Pathol. 1998 Apr;152(4):913-23 [9546352.001]
  • [Cites] Int J Oncol. 1998 Jun;12(6):1327-32 [9592194.001]
  • [Cites] Oncogene. 1998 Jun 11;16(23):2983-7 [9662330.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51 [9671767.001]
  • [Cites] Hepatology. 1998 Aug;28(2):347-59 [9695996.001]
  • [Cites] Eur J Contracept Reprod Health Care. 1998 Dec;3(4):194-200 [10036602.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] AMA J Dis Child. 1956 Feb;91(2):168-86 [13282629.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1211-8 [15887105.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3034-9 [15918185.001]
  • [Cites] Hepatology. 2006 Mar;43(3):515-24 [16496320.001]
  • [Cites] World J Gastroenterol. 2006 Apr 7;12(13):2125-9 [16610069.001]
  • [Cites] Oncogene. 2006 Jun 26;25(27):3778-86 [16799619.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(5):416-20 [17013716.001]
  • [Cites] World J Gastroenterol. 2006 Oct 28;12(40):6567-71 [17072995.001]
  • [Cites] J Surg Oncol. 2006 Dec 1;94(7):587-91 [17066420.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Feb;6(1):52-7 [17287167.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1090-7 [17373745.001]
  • [Cites] Int J Oncol. 2007 Dec;31(6):1379-89 [17982665.001]
  • [Cites] J Hepatol. 2008 Jan;48(1):163-70 [17997499.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7363-9 [18094418.001]
  • [Cites] Hepatology. 2000 Nov;32(5):970-9 [11050047.001]
  • (PMID = 19787833.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2754518
  •  go-up   go-down


63. Sun H, Varela D, Chartier D, Ruben PC, Nattel S, Zamponi GW, Leblanc N: Differential interactions of Na+ channel toxins with T-type Ca2+ channels. J Gen Physiol; 2008 Jul;132(1):101-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two types of voltage-dependent Ca(2+) channels have been identified in heart: high (I(CaL)) and low (I(CaT)) voltage-activated Ca(2+) channels.
  • Ca(2+) currents were recorded using the whole-cell patch clamp technique.
  • While TTX produced no direct effect on I(CaT) elicited by expression of hCa(V)3.1 and hCa(V)3.2 in HEK-293 cells, it significantly attenuated the block of this current by Ni(2+) (IC(50) increased to 550 microM Ni(2+) for Ca(V)3.1 and 15 microM Ni(2+) for Ca(V)3.2); in contrast, 30 microM TTX directly inhibited hCa(V)3.3-induced I(CaT) and the addition of 750 microM Ni(2+) to the TTX-containing medium led to greater block of the current that was not significantly different than that produced by Ni(2+) alone.
  • These findings provide important new implications for our understanding of structure-function relationships of I(CaT) in heart, and further extend the hypothesis of a parallel evolution of Na(+) and Ca(2+) channels from an ancestor with common structural motifs.

  • Hazardous Substances Data Bank. LIDOCAINE .
  • Hazardous Substances Data Bank. TETRODOTOXIN .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biophys J. 1999 Dec;77(6):3034-42 [10585925.001]
  • [Cites] J Gen Physiol. 2003 Jun;121(6):529-40 [12743166.001]
  • [Cites] J Biol Chem. 2000 Mar 3;275(9):6090-100 [10692398.001]
  • [Cites] Circ Res. 2000 Mar 31;86(6):628-35 [10746997.001]
  • [Cites] Neuroreport. 2003 Aug 6;14(11):1537-40 [12960781.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jan;308(1):324-9 [14566004.001]
  • [Cites] Cardiovasc Res. 2004 Sep 1;63(4):653-61 [15306221.001]
  • [Cites] J Gen Physiol. 1985 Jul;86(1):1-30 [2411846.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5340-4 [2425366.001]
  • [Cites] J Gen Physiol. 1989 Jul;94(1):151-67 [2478659.001]
  • [Cites] FEBS Lett. 1991 Nov 18;293(1-2):93-6 [1660007.001]
  • [Cites] Nature. 1992 Apr 2;356(6368):441-3 [1313551.001]
  • [Cites] Science. 1992 May 22;256(5060):1202-5 [1375397.001]
  • [Cites] Science. 1992 Jul 10;257(5067):248-51 [1321496.001]
  • [Cites] Nature. 1993 Mar 4;362(6415):26 [7680430.001]
  • [Cites] J Gen Physiol. 1993 Feb;101(2):153-82 [8384241.001]
  • [Cites] Biophys J. 1994 Jan;66(1):1-13 [8130328.001]
  • [Cites] Physiol Rev. 1994 Apr;74(2):365-507 [8171118.001]
  • [Cites] Receptors Channels. 1995;3(2):71-81 [8581402.001]
  • [Cites] Am J Physiol. 1997 Jul;273(1 Pt 2):H128-37 [9249483.001]
  • [Cites] J Physiol. 1997 Dec 1;505 ( Pt 2):353-69 [9423179.001]
  • [Cites] Science. 1998 Feb 13;279(5353):1027-33 [9461434.001]
  • [Cites] Circ Res. 1998 Jul 13;83(1):103-9 [9670923.001]
  • [Cites] Biophys J. 1998 Dec;75(6):2647-57 [9826589.001]
  • [Cites] Nature. 2005 Apr 7;434(7034):759-63 [15815629.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4823-30 [16377633.001]
  • [Cites] Cell Calcium. 2006 Aug;40(2):205-20 [16766028.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1514-23 [16885209.001]
  • [Cites] Circ Res. 2000 Mar 31;86(6):636-42 [10746998.001]
  • [Cites] Neuron. 2000 Apr;26(1):13-25 [10798388.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2000 Aug;279(2):H692-701 [10924068.001]
  • [Cites] Cardiovasc Res. 2001 Mar;49(4):762-70 [11230975.001]
  • [Cites] Circ Res. 2001 Mar 2;88(4):403-7 [11230107.001]
  • [Cites] Biophys J. 2002 Aug;83(2):912-9 [12124273.001]
  • [Cites] Circ Res. 2002 Nov 1;91(9):790-7 [12411393.001]
  • [Cites] Physiol Rev. 2003 Jan;83(1):117-61 [12506128.001]
  • [Cites] Biophys J. 2003 Jan;84(1):287-94 [12524282.001]
  • [Cites] J Physiol. 2003 Mar 1;547(Pt 2):435-40 [12562928.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2000 Jan;278(1):H184-93 [10644598.001]
  • (PMID = 18591418.001).
  • [ISSN] 1540-7748
  • [Journal-full-title] The Journal of general physiology
  • [ISO-abbreviation] J. Gen. Physiol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR015581; United States / NHLBI NIH HHS / HL / R01 HL075477; United States / NHLBI NIH HHS / HL / 1 R01 HL075477; United States / NCRR NIH HHS / RR / 5P20 RR15581
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CACNA1G protein, human; 0 / CACNA1H protein, human; 0 / CACNA1I protein, human; 0 / Calcium Channel Blockers; 0 / Calcium Channels, L-Type; 0 / Calcium Channels, T-Type; 0 / Marine Toxins; 0 / Sodium Channel Blockers; 27B90X776A / Mibefradil; 35523-89-8 / Saxitoxin; 4368-28-9 / Tetrodotoxin; 7OV03QG267 / Nickel; 98PI200987 / Lidocaine
  • [Other-IDs] NLM/ PMC2442173
  •  go-up   go-down


64. Sloan CD, Shen L, West JD, Wishart HA, Flashman LA, Rabin LA, Santulli RB, Guerin SJ, Rhodes CH, Tsongalis GJ, McAllister TW, Ahles TA, Lee SL, Moore JH, Saykin AJ: Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypes. Am J Med Genet B Neuropsychiatr Genet; 2010 Jul;153B(5):1060-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypes.
  • Hierarchical clustering is frequently used for grouping results in expression or haplotype analyses.
  • Here a hierarchical clustering method is used to analyze the results of an imaging genetics study using multiple brain morphology and cognitive testing endpoints for older adults with amnestic mild cognitive impairment (MCI) or cognitive complaints (CC) compared to healthy controls (HC).
  • The single nucleotide polymorphisms (SNPs) are a subset of those included on a larger array that are found in a reported Alzheimer's disease (AD) and neurodegeneration pathway.
  • The results are consistent with polygenic influences on early neurodegenerative changes and demonstrate the effectiveness of hierarchical clustering in identifying genetic associations among multiple related phenotypic endpoints.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] BMC Bioinformatics. 2003 Dec 11;4:62 [14667254.001]
  • [Cites] BMC Med Genet. 2004 Mar 17;5:6 [15142281.001]
  • [Cites] Brain Res. 1994 Oct 24;661(1-2):147-56 [7834365.001]
  • [Cites] JAMA. 1997 Oct 22-29;278(16):1349-56 [9343467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Neurology. 1999 Apr 22;52(7):1397-403 [10227624.001]
  • [Cites] BMC Bioinformatics. 2004 Oct 8;5:147 [15473905.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):2128-9 [15705655.001]
  • [Cites] J Alzheimers Dis. 2005 Aug;7(4):291-5 [16131730.001]
  • [Cites] J Mol Neurosci. 2005;27(2):167-74 [16186627.001]
  • [Cites] Neurosci Lett. 2006 Jan 9;392(1-2):110-3 [16188386.001]
  • [Cites] Neurobiol Aging. 2006 May;27(5):733-40 [15961190.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1262-70 [16631882.001]
  • [Cites] Trends Neurosci. 2006 May;29(5):280-5 [16545469.001]
  • [Cites] Arch Neurol. 2006 May;63(5):665-72 [16682536.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):508-15 [16772874.001]
  • [Cites] J Neurochem. 2001 Feb;76(4):1121-8 [11181832.001]
  • [Cites] Neurobiol Aging. 2001 Nov-Dec;22(6):863-71 [11754993.001]
  • [Cites] Neurology. 2003 Jan 28;60(2):253-60 [12552040.001]
  • [Cites] Arch Neurol. 2003 Mar;60(3):369-76 [12633148.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Neurology. 2006 Sep 12;67(5):834-42 [16966547.001]
  • [Cites] Biochem Soc Trans. 2006 Dec;34(Pt 6):1277-82 [17073801.001]
  • [Cites] BMC Neurosci. 2006;7:74 [17083736.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):17-23 [17192785.001]
  • [Cites] Clin Neuropsychol. 2007 Jan;21(1):130-45 [17366281.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):11982-95 [17307738.001]
  • [Cites] Neurology. 2007 May 8;68(19):1588-95 [17287448.001]
  • [Cites] Biochem Soc Trans. 2007 Jun;35(Pt 3):574-6 [17511655.001]
  • [Cites] Neurol Clin. 2007 Aug;25(3):577-609, v [17659182.001]
  • [Cites] J Biol Chem. 2007 Sep 7;282(36):26326-34 [17616527.001]
  • [Cites] J Alzheimers Dis. 2007 Aug;12(1):73-92 [17851196.001]
  • [Cites] Curr Alzheimer Res. 2007 Sep;4(4):351-8 [17908036.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):347-53 [17610523.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Adv Genet. 2008;60:3-34 [18358314.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2008 May;63(5):510-7 [18511756.001]
  • [Cites] Neurobiol Dis. 2008 Aug;31(2):188-97 [18559293.001]
  • [Cites] J Clin Psychiatry. 2008 Jul;69(7):1104-11 [18505307.001]
  • [Cites] Nat Rev Neurosci. 2008 Oct;9(10):768-78 [18802446.001]
  • [Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1672-6 [18194457.001]
  • [Cites] J Biol Chem. 2008 Dec 12;283(50):34554-62 [18940800.001]
  • [Cites] J Biol Chem. 2008 Dec 19;283(51):35763-71 [18845544.001]
  • [Cites] J Neurosci. 2008 Dec 31;28(53):14392-400 [19118172.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2263-80 [18624755.001]
  • [Cites] Front Neurol Neurosci. 2009;24:12-9 [19182458.001]
  • [Cites] J Neurosci Res. 2009 Feb 15;87(3):609-16 [18855942.001]
  • [Cites] Biol Pharm Bull. 2009 Mar;32(3):332-6 [19252273.001]
  • [Cites] Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):88-90 [19266703.001]
  • [Cites] J Alzheimers Dis. 2009;16(3):509-11 [19276543.001]
  • [Cites] Semin Cell Dev Biol. 2009 Apr;20(2):175-82 [19429494.001]
  • [Cites] Int Rev Neurobiol. 2009;84:167-84 [19501718.001]
  • [Cites] PLoS One. 2009;4(8):e6501 [19668339.001]
  • [Cites] Curr Alzheimer Res. 2009 Aug;6(4):347-61 [19689234.001]
  • [Cites] Neurology. 2003 Aug 26;61(4):500-6 [12939424.001]
  • [Cites] J Mol Neurosci. 2003;20(3):241-8 [14501003.001]
  • [Cites] Arch Neurol. 2003 Oct;60(10):1394-9 [14568809.001]
  • [Cites] Chin J Physiol. 2003 Sep 30;46(3):111-5 [14672279.001]
  • [Cites] EMBO J. 2004 Feb 11;23(3):483-8 [14749724.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):245-57 [15051507.001]
  • [Cites] Nat Genet. 2004 May;36(5):431-2 [15118671.001]
  • (PMID = 20468060.001).
  • [ISSN] 1552-485X
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG019771; United States / NIA NIH HHS / AG / P30 AG010133; United States / NIA NIH HHS / AG / P30 AG010133-18S1; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NIBIB NIH HHS / EB / U54 EB005149-03; None / None / / U54 EB005149-03; United States / NIA NIH HHS / AG / P30 AG10133-18S1; United States / NIA NIH HHS / AG / R01 AG19771; United States / NIA NIH HHS / AG / R01 AG019771-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS262330; NLM/ PMC3021757
  •  go-up   go-down


65. Gensichen J, Jaeger C, Peitz M, Torge M, Güthlin C, Mergenthal K, Kleppel V, Gerlach FM, Petersen JJ: Health care assistants in primary care depression management: role perception, burdening factors, and disease conception. Ann Fam Med; 2009 Nov-Dec;7(6):513-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health care assistants in primary care depression management: role perception, burdening factors, and disease conception.
  • PURPOSE: In primary care, the involvement of health care assistants (HCAs) in clinical depression management is an innovative approach.
  • Little is known, however, about how HCAs experience their new tasks.
  • We wanted to describe the perceptions and experiences of HCAs who provided case management to patients with depression in small primary care practices.
  • We used a semi-structured instrument to interview 26 HCAs and undertook content analysis.
  • We focussed on 3 key aspects: role perception, burdening factors, and disease conception.
  • RESULTS: Most HCAs said their new role provided them with personal and professional enrichment, and they were interested in improving patient-communication skills.
  • HCAs' disease conception of depression was heterogeneous.
  • After 1 year HCAs believed they were sufficiently familiar with their duties as case managers in depression management.
  • CONCLUSION: HCAs were willing to extend their professional responsibilities from administrative work to more patient-centred work.
  • Even if HCAs perform only monitoring tasks within the case management concept, the resulting workload is a limiting factor.
  • [MeSH-major] Allied Health Personnel / psychology. Depressive Disorder / diagnosis. Practice Management, Medical. Primary Health Care

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Gen Pract. 1998 Jul;48(432):1383-6 [9800394.001]
  • [Cites] J Adv Nurs. 1998 Feb;27(2):399-405 [9515653.001]
  • [Cites] Health Aff (Millwood). 2004 Nov-Dec;23(6):36-47 [15537584.001]
  • [Cites] BMC Public Health. 2005;5:101 [16207375.001]
  • [Cites] BMC Fam Pract. 2006;7:14 [16515692.001]
  • [Cites] Gen Hosp Psychiatry. 2006 Jul-Aug;28(4):296-305 [16814628.001]
  • [Cites] Z Arztl Fortbild Qualitatssich. 2006;100(5):375-82 [16955623.001]
  • [Cites] Adm Policy Ment Health. 2007 Mar;34(2):127-37 [16967338.001]
  • [Cites] Br J Gen Pract. 2007 May;57(538):364-70 [17504586.001]
  • [Cites] Prim Care. 2007 Sep;34(3):571-92, vii [17868760.001]
  • [Cites] Int J Qual Health Care. 2007 Dec;19(6):349-57 [17872937.001]
  • [Cites] Psychol Med. 2008 Feb;38(2):279-87 [17803837.001]
  • [Cites] BMC Health Serv Res. 2007;7:190 [18031573.001]
  • [Cites] Br J Gen Pract. 2008 Feb;58(547):118-24 [18307856.001]
  • [Cites] Ann Fam Med. 2008 Jul-Aug;6(4):331-9 [18626033.001]
  • [Cites] Br J Nurs. 2009 Aug 13-Sep 9;18(15):926, 928-30, 932-3 [19717991.001]
  • [Cites] Ann Intern Med. 2009 Sep 15;151(6):369-78 [19755362.001]
  • [Cites] Br J Clin Psychol. 1999 Sep;38 (Pt 3):215-29 [10532145.001]
  • [Cites] Arch Gen Psychiatry. 1999 Dec;56(12):1109-15 [10591288.001]
  • [Cites] Health Aff (Millwood). 2001 Nov-Dec;20(6):64-78 [11816692.001]
  • [Cites] Nurs Times. 2002 Jul 2-8;98(27):37-8 [12123166.001]
  • [Cites] JAMA. 2002 Dec 11;288(22):2836-45 [12472325.001]
  • [Cites] Nurs Crit Care. 2003 Jul-Aug;8(4):141-8 [12940689.001]
  • [Cites] Br J Gen Pract. 2004 Sep;54(506):679-83 [15353054.001]
  • [Cites] BMJ. 2004 Sep 11;329(7466):602 [15345600.001]
  • [Cites] Manag Care Q. 1996 Spring;4(2):12-25 [10157259.001]
  • [Cites] Br J Gen Pract. 1999 Feb;49(439):103-6 [10326260.001]
  • (PMID = 19901310.001).
  • [ISSN] 1544-1717
  • [Journal-full-title] Annals of family medicine
  • [ISO-abbreviation] Ann Fam Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2775615
  •  go-up   go-down


66. Lougee D, Kemmer TM, Lynch J: An innovative medical civil-military operation training program. Mil Med; 2007 Feb;172(2):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The San Antonio Military Pediatric Center has developed an innovative humanitarian civic assistance (HCA) program.
  • Many medical HCA programs focus on short-term medical interventions and provide transient benefit.
  • This innovative project is a potential model to improve both military training and host nation benefit from HCA programs.

  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357779.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  •  go-up   go-down


67. Rademeyer C, Moore PL, Taylor N, Martin DP, Choge IA, Gray ES, Sheppard HW, Gray C, Morris L, Williamson C, HIVNET 028 study team: Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology; 2007 Nov 10;368(1):172-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hierarchical clustering analysis of neutralization data of the panel viruses predicted phylogenetic relationships between subtype B and C panel viruses, suggesting some subtype-specific neutralization determinants.
  • A similar comparison of subtype C donor viruses showed no significant correlation; however of three donor sequence pairs resolvable by phylogenetic analysis, two were also associated within the neutralization clustering dendrogram, suggesting that closely related viruses may elicit antibodies targeting common neutralization determinants.
  • [MeSH-minor] Adult. Cluster Analysis. Female. HIV Infections / immunology. HIV Infections / virology. Humans. Malawi. Male. Phylogeny. RNA, Viral / genetics. Sequence Analysis, DNA. South Africa. Zambia. Zimbabwe

  • Genetic Alliance. consumer health - HIV.
  • LANL HIV Databases. LANL HIV Databases .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17632196.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI51794; United States / FIC NIH HHS / TW / D43 TW00231; United States / NIAID NIH HHS / AI / N01-AI-45202
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / HIV Envelope Protein gp160; 0 / RNA, Viral; 0 / gp160 protein, Human immunodeficiency virus 1
  •  go-up   go-down


68. Sasaki H, Guleserian KJ, Rose R, Fotiadis C, Boyer PJ, Forbess JM: Hypothermic extracorporeal circulation in immature swine: a comparison of continuous cardiopulmonary bypass, selective antegrade cerebral perfusion and circulatory arrest. Eur J Cardiothorac Surg; 2009 Dec;36(6):992-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypothermic extracorporeal circulation in immature swine: a comparison of continuous cardiopulmonary bypass, selective antegrade cerebral perfusion and circulatory arrest.
  • OBJECTIVE: Selective antegrade cerebral perfusion (SCP) has been widely used during complex congenital heart surgery and theoretically affords some degree of neuroprotection.
  • This study was designed to compare, at profound hypothermia, continuous cardiopulmonary bypass, SCP and circulatory arrest in a survival model of extracorporeal circulation in immature swine.
  • METHODS: Fifteen piglets (5.9+/-1.1 kg) were placed on cardiopulmonary bypass (CPB), cooled to a rectal temperature of 15 degrees C and subjected to 90 min of hypothermic circulatory arrest (HCA), selective cerebral perfusion (30 ml kg(-1)min(-1)) (SCP) or systemic full-flow perfusion (FF; 100 ml kg(-1)min(-1)).
  • RESULTS: The median POD 1 NDS/OPC was 0 (range 0-115)/1(range 1-2) for FF, 130 (range 0-195)/2 (range 1-3) for HCA and 0 (range 0-30)/1 for SCP.
  • Although there was a trend for the neurologic status in the HCA group to be worse on POD 1, this did not achieve significance, and both NDS and OPC scores for HCA animals normalised by POD 5.
  • Median THS was 9 (range, 0-11) for FF, 12 (range, 4-14) for HCA and 9 (range, 0-11) for SCP with no statistically significant difference between the groups.
  • CONCLUSIONS: In this survival model of hypothermic extracorporeal circulatory support in immature swine, histologic brain injury was similar in piglets subjected to FF, SCP or HCA.
  • Although the HCA group tended to have worse early neurologic outcome, any difference clearly disappeared by POD 5.
  • [MeSH-major] Brain Ischemia / prevention & control. Cardiopulmonary Bypass / methods. Cerebrovascular Circulation / physiology. Circulatory Arrest, Deep Hypothermia Induced / methods
  • [MeSH-minor] Animals. Behavior, Animal. Disease Models, Animal. Perfusion / adverse effects. Perfusion / methods. Sus scrofa

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716708.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Pocar M, Passolunghi D, Moneta A, Mattioli R, Donatelli F: Coma might not preclude emergency operation in acute aortic dissection. Ann Thorac Surg; 2006 Apr;81(4):1348-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ascending aorta was always replaced using profound hypothermic circulatory arrest.
  • [MeSH-minor] Acute Disease. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Coma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Apr;81(4):1351-2 [16564271.001]
  • (PMID = 16564270.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


70. Duda DM, Tu C, Fisher SZ, An H, Yoshioka C, Govindasamy L, Laipis PJ, Agbandje-McKenna M, Silverman DN, McKenna R: Human carbonic anhydrase III: structural and kinetic study of catalysis and proton transfer. Biochemistry; 2005 Aug 2;44(30):10046-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The residue phenylalanine 198 (Phe 198) is a prominent cause of the lower activity of human carbonic anhydrase III (HCA III) compared with HCA II and other isozymes which have leucine at this site.
  • We report the crystal structures of HCA III and the site-directed mutant F198L HCA III, both at 2.1 A resolution, and the enhancement of catalytic activity by exogenous proton donors containing imidazole rings.
  • This observation allowed us to comment on a number of possible binding sites for imidazole and derivatives as exogenous proton donors/acceptors in catalysis by HCA III.
  • Kinetic and structural evidence indicates that the phenyl side chain of Phe 198 in HCA III, about 5 A from the zinc, is a steric constriction in the active site, may cause altered interactions at the zinc-bound solvent, and is a binding site for the activation of catalysis by histidylhistidine.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • Hazardous Substances Data Bank. L-Leucine .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042381.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 1Z93/ 1Z97
  • [Grant] United States / NIGMS NIH HHS / GM / GM25154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / His-His-His-His-His-His; 0 / Imidazoles; 0 / Oligopeptides; 0 / Protons; 2ZD004190S / Threonine; 4QD397987E / Histidine; 7GBN705NH1 / imidazole; EC 4.2.1.- / Carbonic Anhydrase III; GMW67QNF9C / Leucine; J41CSQ7QDS / Zinc; K3Z4F929H6 / Lysine
  •  go-up   go-down


76. Cavanaugh JT, Goldvasser D, McGibbon CA, Krebs DE: Comparison of head- and body-velocity trajectories during locomotion among healthy and vestibulopathic subjects. J Rehabil Res Dev; 2005 Mar-Apr;42(2):191-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used high curvature analysis (HCA) to quantify the smoothness of head- and body-velocity trajectories during repeated stepping in 18 vestibulopathic and 17 healthy subjects.
  • We employed a mixed-model repeated measures analysis of variance to compare differences in head- and body-trajectory HCA scores.
  • Pearson coefficients were used to describe relationships between head- and body-trajectory HCA scores within each group.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944884.001).
  • [ISSN] 1938-1352
  • [Journal-full-title] Journal of rehabilitation research and development
  • [ISO-abbreviation] J Rehabil Res Dev
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01AG11255; United States / NCCIH NIH HHS / AT / R21AT00553
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Djaković-Sekulić TL, Smoliński A: Chemometric characterization of s-triazine derivatives in relation to structural parameters and biological activity. Drug Dev Ind Pharm; 2010 Aug;36(8):954-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Principal component analysis (PCA) was performed to explore and visualize similarities and differences among the compounds and among the mobile phases.
  • Observations from the PCA were supported using hierarchical cluster analysis (HCA).
  • [MeSH-minor] Chromatography, Thin Layer. Cluster Analysis. Hydrophobic and Hydrophilic Interactions. Least-Squares Analysis. Models, Biological. Physicochemical Phenomena. Principal Component Analysis. Quantitative Structure-Activity Relationship. Solvents / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20184415.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Herbicides; 0 / Solvents; 0 / Triazines
  •  go-up   go-down


78. Crucitti P, Latora V, Porta S: Centrality measures in spatial networks of urban streets. Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Mar;73(3 Pt 2):036125
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results indicate that a spatial analysis based on a set of four centrality indices allows an extended visualization and characterization of the city structure.
  • A hierarchical clustering analysis based on the distributions of centrality has a certain capacity to distinguish different classes of cities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16605616.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Koutros S, Berndt SI, Sinha R, Ma X, Chatterjee N, Alavanja MC, Zheng T, Huang WY, Hayes RB, Cross AJ: Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. Cancer Res; 2009 Mar 1;69(5):1877-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently reported that heterocyclic amines (HCA) are associated with prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  • We now use extensive genetic data from this resource to determine if risks associated with dietary HCAs {2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP); 2-amino-3,8-dimethylimidazo[4,5-b]quinoxaline (MeIQx); and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx)} from cooked meat are modified by single nucleotide polymorphisms (SNP) in genes involved in HCA metabolism (CYP1A1, CYP1A2, CYP1B1, GSTA1, GSTM1, GSTM3, GSTP1, NAT1, NAT2, SULT1A1, SULT1A2, and UGT1A locus).
  • Unconditional logistic regression was used to estimate odds ratios (OR), 95% confidence intervals (95% CI), and P values for the interaction between SNPs, HCA intake, and risk of prostate cancer.
  • The strongest evidence for an interaction was noted between DiMeIQx and MeIQx and the polymorphism rs11102001 downstream of the GSTM3 locus (P(interaction) = 0.001 for both HCAs; statistically significant after correction for multiple testing).
  • Among men carrying the A variant, the risk of prostate cancer associated with high DiMeIQx intake was 2-fold greater than that with low intake (OR, 2.3; 95% CI, 1.2-4.7).
  • The SNP rs11102001, which encodes a nonsynonymous amino acid change P356S in EPS8L3, is a potential candidate modifier of the effect of HCAs on prostate cancer risk.
  • The observed effect provides evidence to support the hypothesis that HCAs may act as promoters of malignant transformation by altering mitogenic signaling.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):513-20 [12050091.001]
  • [Cites] Pharmacogenetics. 2002 Mar;12(2):145-50 [11875368.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2002;5(2):96-104 [12496996.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2038-44 [10580030.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):266-8 [10667573.001]
  • [Cites] Jpn J Cancer Res. 2000 Jan;91(1):52-8 [10744044.001]
  • [Cites] Cancer Lett. 2000 Jul 3;155(1):55-60 [10814879.001]
  • [Cites] Arch Toxicol. 2000 Jul;74(4-5):222-5 [10959796.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):349S-355S [11189687.001]
  • [Cites] Genomics. 2003 Feb;81(2):234-44 [12620401.001]
  • [Cites] Eur J Endocrinol. 2003 Dec;149(6):469-77 [14640986.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):13-25 [14689577.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] Mol Biol Cell. 2004 Jan;15(1):91-8 [14565974.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):270-6 [14973106.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):293-8 [14973110.001]
  • [Cites] Curr Drug Metab. 2004 Apr;5(2):169-80 [15078194.001]
  • [Cites] J Natl Cancer Inst. 1979 Apr;62(4):833-40 [372655.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Biochem J. 1990 Oct 15;271(2):481-5 [2241927.001]
  • [Cites] Mutat Res. 1991 Mar-Apr;259(3-4):205-17 [2017208.001]
  • [Cites] Eur J Biochem. 1994 Sep 15;224(3):893-9 [7925413.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):195-8 [9000552.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10004-12 [9092542.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):531-6 [9641498.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5340-3 [9850062.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1313-24 [10022813.001]
  • [Cites] Carcinogenesis. 1999 Mar;20(3):353-68 [10190547.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1591-5 [10426812.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(1):69-74 [15685255.001]
  • [Cites] Mol Nutr Food Res. 2005 Jul;49(7):648-55 [15986387.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):8-13 [15880531.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11779-84 [16357191.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):99-107 [16434594.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):756-61 [16614120.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):803-8 [17416774.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Int J Cancer. 2007 Sep 15;121(6):1319-24 [17487839.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1394-401 [17555796.001]
  • [Cites] Cancer Lett. 2007 Oct 8;255(2):205-18 [17537571.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11455-62 [18056474.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):80-7 [18199713.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:197-204 [12351159.001]
  • (PMID = 19223546.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / TU2 CA105666; United States / Intramural NIH HHS / / Z01 CP010152-08
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Heterocyclic Compounds; 0 / Xenobiotics; EC 2.5.1.18 / GSTM3 protein, human; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  • [Other-IDs] NLM/ NIHMS87577; NLM/ PMC2662592
  •  go-up   go-down


80. Bioulac-Sage P, Balabaud C, Zucman-Rossi J: [Interest of immunohistochemistry for the diagnosis of benign hepatocellular tumors]. Ann Pathol; 2010 Dec;30(6):439-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interest of immunohistochemistry for the diagnosis of benign hepatocellular tumors].
  • [Transliterated title] Apport de l'immunohistochimie dans le diagnostic des tumeurs hépatocellulaires bénignes.
  • In this review, we focus on the interest of immunohistochemistry first, to differentiate the two types of benign hepatocellular nodules: focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) and second, to recognize the different subtypes of HCA: HNF1α inactivated HCA, β-catenin activated HCA and inflammatory HCA.
  • Immunohistochemical characteristics described on resected specimen are suitable on biopies of these tumors, facilitating their diagnosis and therefore allowing a better management of the patients.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / analysis. Focal Nodular Hyperplasia / diagnosis. Immunohistochemistry. Liver Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Carcinoma, Hepatocellular / diagnosis. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Glutamate-Ammonia Ligase / analysis. Glutamate-Ammonia Ligase / physiology. Hepatocyte Nuclear Factor 1-alpha / analysis. Hepatocyte Nuclear Factor 1-alpha / genetics. Hepatocyte Nuclear Factor 1-alpha / physiology. Humans. Inflammation. beta Catenin / analysis. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21167430.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / HNF1A protein, human; 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / beta Catenin; EC 6.3.1.2 / Glutamate-Ammonia Ligase
  •  go-up   go-down


81. Smith JS, Ameri F, Gadgil P: Effect of marinades on the formation of heterocyclic amines in grilled beef steaks. J Food Sci; 2008 Aug;73(6):T100-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterocyclic amines (HCAs) are suspected human carcinogens formed in muscle foods during high temperature grilling or cooking.
  • Inhibition of HCAs by commercial marinades rich in polyphenolic antioxidant containing spices was evaluated with beef round steaks cooked at 204 degrees C (400 degrees F).
  • Treatment effects on the levels of 4 HCAs were investigated: 2-amino-3,8-dimethylimidazo[4,5-flquinoxaline (MeIQx), 2-amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine (PhIP), 1-methyl-9H-pyrido[4,3-b]indol (harman), and 9H-pyrido[4,3-blindol (norharman).
  • All 3 marinades, Caribbean, Southwest, and herb, significantly decreased the imidazo-azaarene HCAs (MeIQx, PhIP) as contrasted to controls and liquid blanks.
  • The Caribbean mixture showed the highest decrease in the total HCA content (88%), followed by the herb (72%) and Southwest (57%).
  • With a few exceptions there were significant decreases in HCAs for treatments with only the marinade bases (ingredients without any spices/herbs).
  • Commonly available spice-containing marinades can be effective inhibitors of HCA formation and provide reduced exposure to some of the carcinogens formed during grilling.
  • [MeSH-major] Amines / analysis. Carcinogens / analysis. Food Handling / methods. Heterocyclic Compounds / analysis. Meat Products / analysis
  • [MeSH-minor] Animals. Antioxidants / analysis. Cattle. Cooking / methods. Flavonoids / analysis. Flavoring Agents / pharmacology. Humans. Phenols / analysis. Polyphenols

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241593.001).
  • [ISSN] 0022-1147
  • [Journal-full-title] Journal of food science
  • [ISO-abbreviation] J. Food Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Antioxidants; 0 / Carcinogens; 0 / Flavonoids; 0 / Flavoring Agents; 0 / Heterocyclic Compounds; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


82. Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL, Wang YH: Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol; 2005 Jun 21;11(23):3632-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To detect the expression of Fas ligand (FasL) in colon cancer tissues and cell lines and analyze the function of FasL-expressing colon cancer cells in inducing Fas-sensitive T lymphocyte apoptosis.
  • METHODS: Ninety surgically resected colon cancer tissues and 15 hepatic metastasis specimens were investigated by immunohistochemical method with normal colon mucosa and colon adenoma as control.
  • FasL expression of 4 colon cancer cell lines, SW620, Lovo, LS-174T and SW1116, were detected by Western blotting assay.
  • The function of FasL expressed on colon cancer cells was determined by coculture assay with Jurkat T lymphocytes, the apoptotic rate of which was detected by flow cytometry assay.
  • RESULTS: Fifty-six (62.22%) cases of all the 90 colon cancer tissues and all (100%) the liver metastasis specimens expressed FasL, significantly higher than normal colon mucosa and colonic adenoma.
  • Higher expression of FasL was found in more advanced stage of colon cancer and in cancer tissues with lymphatic or hepatic metastasis.
  • All the colon cancer cell lines were found to express FasL.
  • After coculture with the SW1116 cells for 24 h with an effector: target ratio 10:1, the rate of apoptosis of Jurkat cells rose from 1.9% to 21.0%.
  • [MeSH-minor] Apoptosis / immunology. Cell Line, Tumor. Fas Ligand Protein. Humans. Immunohistochemistry. Intestinal Mucosa / immunology. Intestinal Mucosa / pathology. Jurkat Cells. T-Lymphocytes / cytology. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962391.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ PMC4315977
  •  go-up   go-down


83. Lee EH, Chung HJ, Oh HB, Chi HS, Jee MS, Park SN, Hong SP, Yoo W, Kim SO: [Human papilloma virus genotyping assay using restriction fragment mass polymorphism analysis, and its comparison with sequencing and hybrid capture assays]. Korean J Lab Med; 2007 Feb;27(1):62-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human papilloma virus genotyping assay using restriction fragment mass polymorphism analysis, and its comparison with sequencing and hybrid capture assays].
  • BACKGROUND: Infection with human papilloma virus (HPV) is the main cause of cervical cancer, and HPV genotyping is of increasing importance for determining clinical course and management of the disease based on the HPV genotypes.
  • Here, we established a novel matrix-assisted laser desorption/ ionization time of flight mass spectrometry (MALDI-TOF MS) assay, termed restriction fragment mass polymorphism (RFMP) that is suitable for genotyping multiple HPV in an accurate and high-throughput manner.
  • We evaluated the performance of the RFMP assay in HPV genotyping by comparing the results with those of direct or clonal sequencing and hybrid capture (HC) assays.
  • HPV genotyping was performed with RFMP, sequencing, and HC assays.
  • CONCLUSIONS: RFMP, sequencing, and HC assays were highly concordant with each other in HPV genotyping.
  • Compared to sequencing assay, RFMP assay is found to be advantageous in detecting mixed genotype infections.
  • The accuracy and amenability to high-throughput analysis should make the RFMP assay suitable for reliable screening of HPV genotypes in clinical laboratories.
  • [MeSH-major] Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Genotype. Humans. Nucleic Acid Hybridization / methods. Polymorphism, Restriction Fragment Length. Sequence Analysis, DNA / methods


84. Bleuzen A, Huang C, Olar M, Tchuenbou J, Tranquart F: Diagnostic accuracy of contrast-enhanced ultrasound in focal lesions of the liver using cadence contrast pulse sequencing. Ultraschall Med; 2006 Feb;27(1):40-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of contrast-enhanced ultrasound in focal lesions of the liver using cadence contrast pulse sequencing.
  • The purpose of this study was to assess the accuracy of Cadence Contrast Pulse Sequencing (Siemens-Acuson, CA) method with injection of SonoVue (Bracco Imaging SpA, Italy) for the detection and characterisation of focal liver lesions in comparison with a reference modality during routine use.
  • The underlying liver lesions characterised by a reference modality (including biopsy in 29 lesions) were distributed as follows: haemangioma (n = 56), focal nodular hyperplasia (n = 27), hepatocellular carcinoma (n = 44), hepatocellular adenoma (n = 5), liver metastasis (n = 174), abscess (n = 2), cysts (n = 45), other benign lesions (n = 24) and 3 peritoneal metastases.
  • On the whole, contrast-enhanced ultrasound allowed a complete diagnosis in 96 % of the detected nodules with a significant improvement compared to conventional sonography in which the diagnosis was suspected in only 52 % out of these cases (p < 0.001).
  • CONCLUSION: The present study clearly indicates that contrast-enhanced sonography using Sonovue and Cadence Contrast Pulse Sequencing allows real-time imaging with high accuracy and thus will be a competitive alternative to other modalities such as CT and MR imaging for liver imaging.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Liver Neoplasms / ultrasonography. Ultrasonography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16470478.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


85. Bursch W, Chabicovsky M, Wastl U, Grasl-Kraupp B, Bukowska K, Taper H, Schulte-Hermann R: Apoptosis in stages of mouse hepatocarcinogenesis: failure to counterbalance cell proliferation and to account for strain differences in tumor susceptibility. Toxicol Sci; 2005 May;85(1):515-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis in stages of mouse hepatocarcinogenesis: failure to counterbalance cell proliferation and to account for strain differences in tumor susceptibility.
  • C3H/He and B6C3F1 show much higher liver cancer susceptibility than C57BL/6J mice.
  • We observed (1) earlier appearance of putative preneoplastic foci (PPF), hepatocellular adenoma (HCA), and carcinoma (HCC) in C3H/He than in C57Bl/6J mice and (2) an increase of hepatocellular DNA synthesis in C3H/He and C57Bl/6J mice, compared to normal liver, via PPF and HCA to HCC.
  • PB enhanced DNA synthesis and growth of PPF, in the C3H/He strain only, and of HCA and HCC of both strains.
  • Apoptoses were rare in unaltered livers as well as in preneoplastic lesions, but tended to increase in HCA and HCC of both strains.
  • PB lowered apoptotic activity in PPF of C3H/He mice, but enhanced it in HCA and HCC of C57Bl/6J mice at late stages.
  • In conclusion, the strain difference in growth rates of PPF and tumors is largely determined by higher rates of cell proliferation in C3H/He mice, with and without promotion by PB.
  • Moreover, in C57Bl/6J mice the promoting effect of PB was restricted to HCA and HCC and was not seen in PPF.
  • In contrast with rat liver, inhibition of apoptosis appears to be a minor determinant of tumor promotion in mice.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation / drug effects. Cocarcinogenesis. Liver / pathology. Liver Neoplasms, Experimental / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Animals. Carcinogens / toxicity. Cell Differentiation / drug effects. DNA / biosynthesis. Diethylnitrosamine / toxicity. Male. Mice. Mice, Inbred Strains. Phenobarbital / toxicity. Species Specificity

  • Hazardous Substances Data Bank. Phenobarbital .
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15728704.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 3IQ78TTX1A / Diethylnitrosamine; 9007-49-2 / DNA; YQE403BP4D / Phenobarbital
  •  go-up   go-down


86. Chase LA, Peterson NL, Koerner JF: The lathyrus toxin, beta-N-oxalyl-L-alpha,beta-diaminopropionic acid (ODAP), and homocysteic acid sensitize CA1 pyramidal neurons to cystine and L-2-amino-6-phosphonohexanoic acid. Toxicol Appl Pharmacol; 2007 Feb 15;219(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We now report two additional neurotoxins, the Lathyrus excitotoxin, beta-N-oxalyl-L-alpha,beta-diaminopropionic acid (ODAP), and the endogenous compound, L-homocysteic acid (HCA), sensitize CA1 hippocampal neurons >50-fold to L-AP6 and >10-fold to cystine in a manner similar to QUIS.
  • While the cystine- or L-AP6-mediated depolarization can be inhibited by the non-NMDA receptor antagonist CNQX in ODAP- or QUIS-sensitized slices, the NMDA antagonist D-AP5 inhibits depolarization by cystine or L-AP6 in HCA-sensitized slices.
  • Thus, HCA is the first identified NMDA agonist that induces phosphonate or cystine sensitization.
  • Like QUIS sensitization, the sensitization evoked by either ODAP or HCA can be reversed by a subsequent exposure to 2 mM alpha-aminoadipic acid.
  • [MeSH-major] Amino Acids, Diamino / toxicity. Cystine / pharmacology. Hippocampus / drug effects. Homocysteine / analogs & derivatives. Lathyrus / chemistry. Norleucine / analogs & derivatives. Pyramidal Cells / drug effects
  • [MeSH-minor] 2-Aminoadipic Acid / pharmacology. 6-Cyano-7-nitroquinoxaline-2,3-dione / pharmacology. Animals. Cell Death / drug effects. Dose-Response Relationship, Drug. Electrophysiology. Excitatory Amino Acid Agonists / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. In Vitro Techniques. Male. Organophosphonates / pharmacology. Quisqualic Acid / pharmacology. Rats. Rats, Sprague-Dawley. Receptors, Glutamate / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Receptors, Presynaptic / drug effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234231.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 35073
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids, Diamino; 0 / Excitatory Amino Acid Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Organophosphonates; 0 / Receptors, Glutamate; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Receptors, Presynaptic; 0LVT1QZ0BA / Homocysteine; 1001-13-4 / homocysteic acid; 1K7B1OED4N / 2-Aminoadipic Acid; 48TCX9A1VT / Cystine; 6OTE87SCCW / 6-Cyano-7-nitroquinoxaline-2,3-dione; 7554-90-7 / oxalyldiaminopropionic acid; 78944-89-5 / 2-amino-6-phosphonohexanoic acid; 832C8OV84S / Norleucine; 8OC22C1B99 / Quisqualic Acid
  •  go-up   go-down


87. Temperini C, Scozzafava A, Vullo D, Supuran CT: Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry; 2006 Sep 18;12(27):7057-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme.
  • Activation of six human carbonic anhydrases (CA, EC 4.2.1.1), that is, hCA I, II, IV, VA, VII, and XIV, with l- and d-histidine was investigated through kinetics and by X-ray crystallography. l-His was a potent activator of isozymes I, VA, VII, and XIV, and a weaker activator of hCA II and IV. d-His showed good hCA I, VA, and VII activation properties, being a moderate activator of hCA XIV and a weak activator of hCA II and IV.
  • The structures as determined by X-ray crystallography of the hCA II-l-His/d-His adducts showed the activators to be anchored at the entrance of the active site, contributing to extended networks of hydrogen bonds with amino acid residues/water molecules present in the cavity, explaining their different potency and interaction patterns with various isozymes.
  • This is the first study showing different binding modes of stereoisomeric activators within the hCA II active site, with consequences for overall proton-transfer processes (rate-determining for the catalytic cycle).
  • The study also points out differences of activation efficiency between various isozymes with structurally related activators, convenient for designing alternative proton-transfer pathways, useful both for a better understanding of the catalytic mechanism and for obtaining pharmacologically useful derivatives, for example, for the management of Alzheimer's disease.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807956.001).
  • [ISSN] 0947-6539
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Activators; 0 / Isoenzymes; 4QD397987E / Histidine; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


88. Shomori K, Nishihara K, Tamura T, Tatebe S, Horie Y, Nosaka K, Haruki T, Hamamoto Y, Shiomi T, Nakabayashi M, Ito H: Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. Gastric Cancer; 2010 Aug;13(3):177-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance.
  • BACKGROUND: Geminin negatively regulates Cdt1 and induces the formation of prereplicative complexes by loading mini-chromosome maintenance proteins (Mcm) onto chromatin and limiting DNA replication to once per cell cycle.
  • Recent studies have suggested that geminin expression is a marker of the S/G2/M phase of the cell cycle and is associated with a poor prognosis in various human malignancies.
  • METHODS: We performed western blot analysis of seven human gastric cancer cell lines, and immunohistochemical analysis of 72 gastric mucosal lesions and 128 surgically removed advanced intestinal-type gastric carcinomas.
  • RESULTS: Geminin was detected in all cell lines.
  • Geminin labeling indices (LIs) in hyperplastic polyps, low-grade adenomas, high-grade adenomas, and intestinal-type adenocarcinomas were 3.9%, 10.5%, 18.6%, and 27.2%, respectively.
  • Double-labeling immunofluorescence revealed coexpression of geminin and Ki67 in both normal and tumor cells.
  • Univariate Cox regression analysis indicated that the overall survival of stage I-IV tumors was significantly correlated with high geminin LIs (relative risk [RR] = 1.94; P = 0.04).
  • [MeSH-major] Cell Cycle Proteins / analysis. Ki-67 Antigen / analysis. Nuclear Proteins / analysis. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenoma / mortality. Adenoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Female. Fluorescent Antibody Technique. Geminin. Humans. Hyperplasia. Immunohistochemistry. Intestinal Neoplasms / mortality. Intestinal Neoplasms / pathology. Japan. Kaplan-Meier Estimate. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Multivariate Analysis. Polyps / mortality. Polyps / pathology. Prognosis. Regression Analysis. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):959-70 [19240714.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1802-11 [14583787.001]
  • [Cites] Genes Cells. 2002 Jun;7(6):523-34 [12059957.001]
  • [Cites] Tumori. 2008 Jul-Aug;94(4):531-8 [18822690.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(7):1207-20 [16487741.001]
  • [Cites] EMBO J. 1991 Apr;10(4):857-64 [2009861.001]
  • [Cites] Biophys J. 1963 Jan;3:11-33 [13980635.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Liver Int. 2006 May;26(4):424-32 [16629645.001]
  • [Cites] J Pathol. 2004 Oct;204(2):121-30 [15376260.001]
  • [Cites] Science. 2000 Dec 22;290(5500):2309-12 [11125146.001]
  • [Cites] J Cell Physiol. 2005 Jan;202(1):215-22 [15389519.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Eur Surg Res. 1990;22(6):365-70 [2079097.001]
  • [Cites] Semin Diagn Pathol. 2002 Feb;19(1):20-30 [11936263.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Oncol Rep. 2009 May;21(5):1189-95 [19360293.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):267-73 [12107111.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2008;11(1):37-46 [18373176.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):949-56 [17262828.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2496-503 [7139542.001]
  • [Cites] J Oral Pathol Med. 2010 Apr;39(4):328-34 [20136698.001]
  • [Cites] Histopathology. 2003 Jun;42(6):566-74 [12786892.001]
  • [Cites] Hum Pathol. 2009 Jul;40(7):975-81 [19269009.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 30;305(2):412-20 [12745091.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3210-6 [17664468.001]
  • [Cites] Neoplasma. 2005;52(5):420-4 [16151588.001]
  • [Cites] Gastrointest Endosc. 1992 Jul-Aug;38(4):481-4 [1511825.001]
  • [Cites] Cell. 1998 Jun 12;93(6):1043-53 [9635433.001]
  • (PMID = 20820987.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


89. Galloro V: HCA initiates Texas two-step. Allegations spur Baylor joint-venture investigations. Mod Healthc; 2006 May 15;36(20):8-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA initiates Texas two-step. Allegations spur Baylor joint-venture investigations.

  • MedlinePlus Health Information. consumer health - Health Fraud.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752858.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] Legal Cases; News
  • [Publication-country] United States
  •  go-up   go-down


90. Galloro V: LifePoint rethinks HCA deal. Renegotiations are under way for five hospitals. Mod Healthc; 2006 Apr 10;36(15):8-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LifePoint rethinks HCA deal. Renegotiations are under way for five hospitals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671188.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


91. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, Deliliers GL, Neri A: A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer; 2009 Jul;48(7):603-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We firstly generated genome-wide profiles of 41 MMs and four plasma cell leukemias, using a self-developed procedure to infer exact local copy numbers (CNs) for each sample.
  • Our analysis allowed the identification of a significant fraction of patients showing near-tetraploidy.
  • Furthermore, a conventional hierarchical clustering analysis showed that near-tetraploidy, 1q gain, hyperdiploidy, and recursive deletions at 1p and chromosomes 13, 14, and 22 were the main aberrations driving samples grouping.
  • A multiclass analysis of transcriptional profiles characterizing the different clusters showed marked gene-dosage effects, particularly concerning 1q transcripts; this finding was also confirmed by a nonparametric analysis between normalized gene expression levels and local CN variations (1027 highly-significant correlated genes).
  • [MeSH-major] Allelic Imbalance. Gene Dosage. In Situ Hybridization, Fluorescence / methods. Multiple Myeloma / genetics. Oligonucleotide Array Sequence Analysis / methods. Polymorphism, Single Nucleotide
  • [MeSH-minor] Aged. Aged, 80 and over. Chromosome Aberrations. Chromosome Mapping. Cluster Analysis. Female. Gene Expression Profiling. Genome, Human. Humans. Loss of Heterozygosity. Male. Middle Aged. Oxidoreductases / genetics. Oxidoreductases / metabolism. Retinoblastoma Protein / genetics. Retinoblastoma Protein / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396863.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human
  •  go-up   go-down


92. Tan ST, Zhu H, Chew W: Self-modeling curve resolution of multi-component vibrational spectroscopic data using automatic band-target entropy minimization (AutoBTEM). Anal Chim Acta; 2009 Apr 20;639(1-2):29-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This AutoBTEM is a variant extension of the band-target entropy minimization (BTEM) that combines a novel automatic band-targeting numerical strategy with exhaustive BTEM curve resolutions and unsupervised hierarchical clustering analysis in an overall blind search approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345755.001).
  • [ISSN] 1873-4324
  • [Journal-full-title] Analytica chimica acta
  • [ISO-abbreviation] Anal. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


93. Sun XJ, Sun KL, Zheng ZH, Fu WN, Hao DM, Xu HM, Li XM: Gene expression patterns in gastric cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr;23(2):142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hierarchical clustering was performed to clarify genes in association with distinct stages of GC.
  • Hierarchical clustering analysis separated the differentially expressed genes in different stages of GC into 5 main characteristic groups.
  • [MeSH-major] DNA, Neoplasm / analysis. Gene Expression Profiling. Stomach Neoplasms / metabolism
  • [MeSH-minor] Gene Expression. Gene Expression Regulation, Neoplastic. Gene Library. Humans. Microarray Analysis. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604482.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


94. Bhattacharya B, Cai J, Luo Y, Miura T, Mejido J, Brimble SN, Zeng X, Schulz TC, Rao MS, Puri RK: Comparison of the gene expression profile of undifferentiated human embryonic stem cell lines and differentiating embryoid bodies. BMC Dev Biol; 2005;5:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the gene expression profile of undifferentiated human embryonic stem cell lines and differentiating embryoid bodies.
  • BACKGROUND: The identification of molecular pathways of differentiation of embryonic stem cells (hESC) is critical for the development of stem cell based medical therapies.
  • RESULTS: Previously identified "stemness" genes in undifferentiated hESC lines showed down modulation in differentiated cells while expression of several genes was induced as cells differentiated.
  • Gene expression was validated by a variety of techniques including another large scale array, reverse transcription polymerase chain reaction, focused cDNA microarrays, massively parallel signature sequencing (MPSS) analysis and immunocytochemisty.
  • A hierarchical clustering analysis clearly depicted a distinct difference in gene expression profile among undifferentiated and differentiated hESC and confirmed that microarray analysis could readily distinguish them.
  • [MeSH-major] Cell Differentiation / genetics. Embryo, Mammalian / cytology. Gene Expression Profiling / methods. Stem Cells / cytology
  • [MeSH-minor] Biomarkers. Cluster Analysis. Databases, Nucleic Acid. Expressed Sequence Tags. Gene Expression Regulation. Humans. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Dyn. 2004 May;230(1):187-98 [15108323.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3444-53 [15064731.001]
  • [Cites] BMC Neurosci. 2003 Oct 22;4:27 [14572319.001]
  • [Cites] Nat Biotechnol. 2004 Jun;22(6):707-16 [15146197.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4434-41 [15231652.001]
  • [Cites] Cell Physiol Biochem. 2004;14(4-6):187-96 [15319521.001]
  • [Cites] BMC Dev Biol. 2004 Aug 10;4:10 [15304200.001]
  • [Cites] Biotechnol Bioeng. 2004 Nov 5;88(3):273-86 [15493035.001]
  • [Cites] Dev Biol. 2004 Nov 15;275(2):269-86 [15501218.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7844-8 [7544005.001]
  • [Cites] Neuron. 1997 Oct;19(4):773-85 [9354325.001]
  • [Cites] Science. 1998 Nov 6;282(5391):1145-7 [9804556.001]
  • [Cites] Gene. 1998 Dec 11;224(1-2):77-86 [9931445.001]
  • [Cites] J Neurosci Res. 2004 Dec 1;78(5):637-46 [15499592.001]
  • [Cites] Stem Cells Dev. 2004 Dec;13(6):694-715 [15684837.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1603-14 [15883170.001]
  • [Cites] Stem Cells Dev. 2005 Jun;14(3):270-84 [15969622.001]
  • [Cites] Dev Growth Differ. 2005 Jun;47(5):295-306 [16026538.001]
  • [Cites] Biol Reprod. 2005 Dec;73(6):1147-56 [16079311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1665-70 [10677516.001]
  • [Cites] Theriogenology. 1999 Jul 15;52(2):195-212 [10734388.001]
  • [Cites] Nat Genet. 2000 Apr;24(4):372-6 [10742100.001]
  • [Cites] Nat Biotechnol. 2000 Apr;18(4):399-404 [10748519.001]
  • [Cites] Nat Biotechnol. 2000 Jun;18(6):630-4 [10835600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11307-12 [11027332.001]
  • [Cites] Dev Biol. 2000 Nov 15;227(2):271-8 [11071754.001]
  • [Cites] Dev Biol. 2001 Mar 15;231(2):321-33 [11237462.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):971-4 [11581665.001]
  • [Cites] Exp Neurol. 2001 Dec;172(2):383-97 [11716562.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):365-71 [11726920.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):329-39 [11839785.001]
  • [Cites] J Anat. 2002 Mar;200(Pt 3):225-32 [12033726.001]
  • [Cites] J Anat. 2002 Mar;200(Pt 3):249-58 [12033729.001]
  • [Cites] Genome Res. 2002 Dec;12(12):1921-8 [12466296.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):6-11 [12517768.001]
  • [Cites] Cloning Stem Cells. 2003;5(1):79-88 [12713704.001]
  • [Cites] Stem Cells. 2003;21(5):521-6 [12968106.001]
  • [Cites] Stem Cells. 2004;22(1):51-64 [14688391.001]
  • [Cites] Cells Tissues Organs. 2004;176(1-3):41-53 [14745234.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):987-94 [15010839.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2956-64 [15070671.001]
  • [Cites] Dev Biol. 2004 May 15;269(2):360-80 [15110706.001]
  • (PMID = 16207381.001).
  • [ISSN] 1471-213X
  • [Journal-full-title] BMC developmental biology
  • [ISO-abbreviation] BMC Dev. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Other-IDs] NLM/ PMC1260016
  •  go-up   go-down


95. Shiono M, Hata M, Sezai A, Negishi N, Sezai Y: Surgical results in acute type A aortic dissection. Ann Thorac Cardiovasc Surg; 2005 Feb;11(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We were able to benefit greatly by various innovative technologies which include open distal anastomosis using hypothermic circulatory arrest with antegrade cerebral perfusion, gelatin-resorcin-formaldehyde (GRF) glue, branched presealed Dacron graft, and antegrade arterial perfusion.
  • [MeSH-minor] Acute Disease. Age Factors. Cardiopulmonary Bypass. Hospitals, University. Humans. Japan. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Vascular Surgical Procedures / methods. Vascular Surgical Procedures / mortality

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788966.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR: Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood; 2007 Jul 15;110(2):490-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.
  • Sirolimus-based immunosuppressive regimens in organ transplantation have been associated with a lower than expected incidence of cytomegalovirus (CMV) disease.
  • Whether sirolimus has a similar effect on CMV reactivation after allogeneic hematopoietic stem cell transplantation (HSCT) is not known.
  • The cohort included 252 patients who received sirolimus-tacrolimus for graft-versus-host disease (GVHD) prophylaxis; the rest received non-sirolimus-based regimens.
  • An initial positive CMV DNA hybrid capture assay was observed in 225 patients (37.1%) at a median 39 days after HSCT for an incidence rate of 0.50 cases/100 patient-days (95% confidence interval [CI], 0.44-0.57).
  • [MeSH-major] Cytomegalovirus Infections / prevention & control. Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation / adverse effects. Immunosuppressive Agents / therapeutic use. Sirolimus / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Mar;25(6):665-72 [10734302.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4357-63 [12036862.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2062-8 [10979948.001]
  • [Cites] Bone Marrow Transplant. 2002 Jun;29(11):903-6 [12080355.001]
  • [Cites] Transplantation. 2002 Jul 15;74(1):49-54 [12134098.001]
  • [Cites] Blood. 2003 May 15;101(10):4195-200 [12531791.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1601-5 [12730113.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Sep;9(9):543-58 [14506657.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3060-7 [12843000.001]
  • [Cites] Clin Microbiol Rev. 2003 Oct;16(4):647-57 [14557291.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5159-66 [14605153.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):662-70 [14616970.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(2):197-204 [14647256.001]
  • [Cites] Transpl Infect Dis. 2003 Dec;5(4):174-80 [14987201.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2003-8 [14644993.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 May;10(5):328-36 [15111932.001]
  • [Cites] Bone Marrow Transplant. 2004 Sep;34(6):471-6 [15273708.001]
  • [Cites] J Virol. 2004 Oct;78(20):11030-9 [15452223.001]
  • [Cites] J Infect Dis. 1986 Mar;153(3):478-88 [3005424.001]
  • [Cites] Blood. 1986 Apr;67(4):1162-7 [3006831.001]
  • [Cites] Scand J Infect Dis. 1986;18(3):199-209 [3016884.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):70-5 [2827025.001]
  • [Cites] Blood. 1988 May;71(5):1432-7 [2833959.001]
  • [Cites] Rev Infect Dis. 1990 Sep-Oct;12 Suppl 7:S793-804 [2173108.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1601-7 [1658652.001]
  • [Cites] Ann Intern Med. 1993 Feb 1;118(3):179-84 [8380243.001]
  • [Cites] Lancet. 1994 Mar 26;343(8900):749-53 [7907729.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2815-20 [7670117.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Blood. 1996 Nov 15;88(10):4063-71 [8916975.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):241-8 [9028553.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2303-14 [9746768.001]
  • [Cites] Transplantation. 1998 Nov 27;66(10):1330-4 [9846518.001]
  • [Cites] J Clin Microbiol. 1999 Apr;37(4):958-63 [10074509.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):987-94 [15489873.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1810-4 [15459007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4140-5 [15738399.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7 [15983555.001]
  • [Cites] Haematologica. 2006 Jan;91(1):78-83 [16434374.001]
  • [Cites] Blood. 2006 Apr 1;107(7):3002-8 [16352807.001]
  • [Cites] Bone Marrow Transplant. 2006 May;37(9):851-6 [16532016.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(2):CD004290 [16625599.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 May;12(5):552-9 [16635790.001]
  • [Cites] Am J Transplant. 2006 Jun;6(6):1377-86 [16686761.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jun;12(6):635-40 [16737936.001]
  • [Cites] J Gen Virol. 2006 Jul;87(Pt 7):1763-79 [16760381.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14182-7 [16959881.001]
  • [Cites] Gene. 2006 Dec 15;384:120-8 [16989963.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3108-14 [17138818.001]
  • [Cites] Biol Blood Marrow Transplant. 2013 Mar;19(3):481-5 [23247045.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):228-36 [11167809.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1152-9 [11181681.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1978-85 [11877269.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3):280-8 [10871153.001]
  • (PMID = 17392502.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL070149; United States / NHLBI NIH HHS / HL / HL070149
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1924486
  •  go-up   go-down


97. Crucitti P, Latora V, Porta S: Centrality in networks of urban streets. Chaos; 2006 Mar;16(1):015113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results indicate that a spatial analysis, that we term multiple centrality assessment, grounded not on a single but on a set of different centrality indices, allows an extended comprehension of the city structure, nicely capturing the skeleton of most central routes and subareas that so much impacts on spatial cognition and on collective dynamical behaviors.
  • Hierarchical clustering analysis, based either on the Gini coefficients of the centrality distributions, or on the correlation between different centrality measures, is able to characterize classes of cities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599779.001).
  • [ISSN] 1054-1500
  • [Journal-full-title] Chaos (Woodbury, N.Y.)
  • [ISO-abbreviation] Chaos
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Becker C: HCA's private ambitions. What twists could the industry expect this time? Mod Healthc; 2006 Jul 31;36(30):8-9, 16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA's private ambitions. What twists could the industry expect this time?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16913009.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


99. Psatha EA, Semelka RC, Armao D, Woosley JT, Firat Z, Schneider G: Hepatocellular adenomas in men: MRI findings in four patients. J Magn Reson Imaging; 2005 Aug;22(2):258-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular adenomas in men: MRI findings in four patients.
  • PURPOSE: To demonstrate both MRI and histopathological findings of hepatocellular adenomas (HCAs) in men.
  • MATERIALS AND METHODS: HCAs in four men are reported.
  • RESULTS: Three men had solitary non-hemorrhagic adenomas that exhibited a uniform capillary blush with no central scar, and uniform fading of the tumor to near isointensity with the liver parenchyma by one minute.
  • One patient had a solitary hemorrhagic adenoma that measured 17 cm in diameter and was heterogeneous on all sequences.
  • CONCLUSIONS: Although three of the four patients had tumors that exhibited uniform homogeneous tumor blush and rapid fading of enhancement, because HCAs are rare in men and resemble hepatocellular carcinoma (HCC) in appearance, our findings suggest that histological confirmation of HCAs may not be avoidable in men.
  • [MeSH-major] Adenoma, Liver Cell / diagnosis. Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Radiographic Image Enhancement
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Contrast Media. Diagnosis, Differential. Gadolinium DTPA. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16028257.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


100. Liao CC, Mehta A, Ward NJ, Marsh S, Arulampalam T, Norton JD: Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World J Surg Oncol; 2010;8:33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study.
  • In a pilot methodological study, we have evaluated the changes in protein expression profiles of sera from CRC patients that occur following surgery to establish the potential of this approach for monitoring post-surgical response and possible early prediction of disease recurrence.
  • These were used to classify post-operative sera by hierarchical clustering analysis (Spearman's Rank correlation) and, as an independent 'test' dataset, by k-nearest neighbour and weighted voting supervised learning algorithms.
  • RESULTS: Hierarchical cluster analysis classified post-operative sera from all six early Dukes' stage (A and B) patients as normal.
  • Analysis by supervised learning algorithms similarly grouped all advanced Dukes' stages as cancer, with four of the six post-operative sera from early Dukes' stages being classified as normal (P = 0.045; Fisher's exact test).
  • CONCLUSIONS: The results of this pilot methodological study illustrate the proof-of-concept of using protein expression profiling of post-surgical blood sera from individual patients to monitor disease course.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Colorectal Neoplasms / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Algorithms. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Prognosis. Proteomics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Jul;14(7):1026-38 [12853343.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1453-4 [14871861.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Ann R Coll Surg Engl. 1992 Jan;74(1):63-7 [1736798.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1143-54 [16083265.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1068-76 [16603345.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]
  • [Cites] Bioinformatics. 2006 Aug 1;22(15):1924-5 [16709585.001]
  • [Cites] World J Gastroenterol. 2006 Nov 7;12(41):6594-601 [17075970.001]
  • [Cites] Nat Rev Cancer. 2006 Dec;6(12):961-7 [17093504.001]
  • [Cites] Oncologist. 2007 Jan;12(1):38-50 [17227899.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):259-66 [17245180.001]
  • [Cites] Exp Oncol. 2006 Dec;28(4):282-7 [17285111.001]
  • [Cites] Clin Chem. 2007 May;53(5):852-8 [17395711.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] Gut. 2007 Oct;56(10):1419-25 [17494107.001]
  • [Cites] Mol Diagn Ther. 2008;12(2):77-85 [18422372.001]
  • [Cites] Mol Diagn Ther. 2008;12(2):87-98 [18422373.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):346-54 [18556775.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD005390 [18646127.001]
  • [Cites] World J Surg Oncol. 2009;7:36 [19338662.001]
  • [Cites] Nat Rev Cancer. 2009 Jul;9(7):489-99 [19536109.001]
  • [Cites] Clin Transl Oncol. 2009 Aug;11(8):526-33 [19661027.001]
  • [Cites] BMC Cancer. 2009;9:287 [19689818.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • (PMID = 20420661.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  • [Other-IDs] NLM/ PMC2873338
  •  go-up   go-down






Advertisement